

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
21 December 2007 (21.12.2007)

PCT

(10) International Publication Number
WO 2007/145661 A2

(51) International Patent Classification:

C12Q 1/68 (2006.01)

(21) International Application Number:

PCT/US2006/045761

(22) International Filing Date:

29 November 2006 (29.11.2006)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/740,887 30 November 2005 (30.11.2005) US

(71) Applicant (for all designated States except US): **GUILD ASSOCIATES, INC.** [US/US]; 5750 Shier-rings Road, Dublin, OH 43016 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **SCHOFIELD, David, Alexander** [GB/US]; 4711 Hard Scuffle Lane, Hollywood, SC 29449 (US). **DINOVO, Augustine, Anthony** [US/US]; 1469 Kentwood Circle, Charleston, SC 29412 (US).

(74) Agent: **BIRKENMEIER, Guy, F.**; Baker Botts L.L.P., 98 San Jacinto Blvd., 1500 San Jacinto Center, Austin, TX 78701 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:


- as to the identity of the inventor (Rule 4.17(i))
- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

Published:

- without international search report and to be republished upon receipt of that report
- with sequence listing part of description published separately in electronic form and available upon request from the International Bureau

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: DIFFERENTIALLY FLUORESCENT YEAST BIOSENSORS FOR THE DETECTION AND BIODEGRADATION OF CHEMICAL AGENTS



(57) Abstract: The present disclosure provides methods, devices, systems and compositions for detecting and/or modifying chemical agents. In some embodiments, a biosensor may be configured to detect a chemical agent, modify that agent to a form with reduced toxicity, and and/or detect the modified form of the chemical agent.

WO 2007/145661 A2

DIFFERENTIALLY FLUORESCENT YEAST BIOSENSORS FOR THE DETECTION AND BIODEGRADATION OF CHEMICAL AGENTS

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Application No. 60/740,887 filed November 30, 2005, the contents of which are incorporated herein, in their entirety, by reference.

5

TECHNICAL FIELD

The present disclosure relates to systems, organisms, and methods of sensing an analyte and/or product(s) of analyte transformation.

10 BACKGROUND

Chemical weapons such as organophosphate (OP) nerve agents, although developed nearly 100 years ago, continue to be a serious threat to both army and civilian personnel. Nerve agents were used during the 1980's Iraq/Iran war, by the Japanese Aum Shinrikyo terrorist cult in the Matsumoto attack of 1994, and in the
15 1995 Tokyo subway attack. In this latter incident, the terrorists left a plastic bag with the volatile nerve agent sarin on an underground train and pierced the bags with the tips of their umbrellas before escaping. The resulting vapor injured 3,796 people, caused 12 deaths and mass panic. OP nerve agents are particularly suited as weapons of mass destruction since they are generally cheap and are relatively easy to produce
20 by developing nations or terrorists. Nerve agents may be particularly hazardous since they may be easily dispersed, they may be easily concealed, and they may be lethal in small quantities. For example, by some calculations, circulating air within a 250m³ airplane passenger compartment may be rendered lethal in about 2.5 minutes by the vapor from a teaspoon of liquid sarin. The resulting vapor may be readily absorbed
25 through the skin or inhaled and may result in rapid incapacitation and death. Other OP nerve agents such as VX (O-ethyl S-[2-diisopropylaminoethyl] methylphosphonothiolate), although less volatile than sarin, may be even more deadly since only miniscule amounts of liquid are needed to be lethal. Aerosolized VX droplets could be dispersed by simple spraying (*e.g.*, using a crop duster) or by a more

conventional missile attack. Nerve agents may act by inhibiting the enzyme acetylcholinesterase (AChE). AChE is a very efficient enzyme that hydrolyzes approximately 10,000 acetylcholine (ACh) molecules per second. Consequently, AChE inhibition by nerve gases causes near instantaneous ACh flooding. This may
5 result in respiratory symptoms, chest tightness, dimming of vision and eye pain and in severe cases of exposure vomiting, abdominal pain, bladder/bowel hyperactivity, incontinence, convulsions, respiratory failure, paralysis and death.

The threat of OP nerve agents is compounded by the fact that some countries have massive stockpiles. World stockpiles are reported to exceed 200 kilotons, with
10 U.S. reserves alone amounting to 30 kilotons. In addition, OP compounds are widely used in agricultural and domestic pest controls such as pesticides. For example, in the U.S. over 40 million kg of OP pesticides are used annually, with another 20 million kg produced annually for export. With this overuse, there are legitimate public health concerns about OP contamination of soil and water systems. Unintentional exposure
15 (water, food, soil) to OP pesticides may cause 1 to 3 million cases of pesticide poisonings annually worldwide.

SUMMARY

Accordingly, there is a need for safe and effective methods to dispose of these
20 man-made toxic compounds and for self-sustainable detection systems. The present disclosure relates to biosensors for detecting (1) one or more analytes (*e.g.*, chemical agents) and/or (2) the transformation (*e.g.*, degradation) of one or more analytes (*e.g.*, chemical agents). Biosensors of the disclosure may be useful in any application where it is desirable to detect and/or transform (*e.g.*, remove) a species of interest.
25 For example, according to some embodiments, a biosensor may be used to detect and/or remove a chemical contaminant in a production process and/or a hazardous environment.

In some embodiments, a biosensor may include a microbe. For example, a biosensor of the disclosure may include a genetically engineered strain of yeast (*e.g.*,
30 *Saccharomyces cerevisiae*). A yeast may (i) fluoresce more in the presence of an analyte (*e.g.*, contact with a nerve gas warfare agent and/or pesticide) than in the

absence of the analyte, (ii) transform (*e.g.*, hydrolyze) the analyte, and/or (iii) differentially fluoresce upon transformation of the analyte.

A yeast, in some embodiments, may include promoters, coding sequences, proteins, and/or other components for transforming (*e.g.*, degrading) one or more
5 analytes. A yeast may also include promoters, coding sequences, proteins, and/or other components for detecting one or more analytes. For example, a yeast may be genetically engineered to (i) express enzymes not normally found in yeast in order to confer the ability to biodegrade a chemical agent and; (ii) possess a dual fluorescent reporter system transcriptionally fused to yeast promoters which are differentially
10 activated to fluoresce at one wavelength in the presence of the chemical agent contamination or another wavelength in the presence of the biodegraded products.

The yeast *S. cerevisiae*, which is a robust non-pathogenic microorganism that is resistant to environmental extremes, may be used as a self-contained biosensor according to some embodiments of the disclosure. Exogenous substrates and/or
15 consumables may not be required. In addition, a simple hand-held illumination device may allow distinct visual detection of the chemical agent contamination and biodegraded products in embodiments using a dual fluorescent reporter system.

The present disclosure further relates to detecting transformation of an analyte. In some embodiments of the disclosure, transformation of an analyte may include
20 partial and/or complete degradation (*e.g.*, hydrolysis) of the analyte. Transformation may include converting (*e.g.*, anabolically or catabolically) an analyte to another form. For example, an analyte may be conjugated to another molecule and/or integrated into a larger molecule. An analyte transformation product may be more innocuous (*e.g.*, less toxic) than its parent analyte.

25 In some embodiments an analyte may be an organophosphate.

In some embodiments, the present disclosure relates to a yeast biosensor comprising (a) a first expression control sequence operably linked to a first nucleic acid encoding a first reporter, wherein said first expression control sequence drives expression of the first reporter if an organophosphate is present, (b) a second
30 expression control sequence operably linked to a second nucleic acid encoding a second reporter, wherein said second expression control sequence drives expression of the second reporter if an organophosphate hydrolytic product is present, and (c) at

least one enzyme that hydrolyzes the organophosphate to produce the organophosphate hydrolytic product. The first and/or second reporter may comprise a nucleic acid encoding a fluorescent protein, a light protein, an enzyme, and/or an ice nucleation protein (*inaZ*). A fluorescent protein may comprise a green fluorescent protein (GFP) or its variants (*e.g.*, enhanced GFP (EGFP), yeast enhanced GFP (YeGFP), *Aequorea coerelescens* GFP (AcGFP)), DsRed or its variants (*e.g.*, DsRed monomer, DsRed2, DsRed express), RedStar2, ASRed2, HcRed1, AmCyan1, ZsYellow1, ZsGreen1, and/or AmCyan1. A light protein may comprise insect luciferase (*luc*), bacterial luciferase (*luxAB*), bacterial bioluminescence (*luxCDABE*), and/or *Renilla* luciferase (*luc*). An enzyme may comprise uroporphyrinogen III methyltransferase (*cobA*), secreted alkaline phosphatase (SEAP), β -galactosidase, and/or β -glucuronidase (GUS).

The first and second reporters, according to some embodiments, may be different from each other. A first expression control sequence may comprise nucleotides -500 to -1 (*e.g.*, nucleotides -1000 to -1) of a gene selected from the group consisting of Accession No. YGR035C, Accession No. YHR139C, Accession No. YOR186W, Accession No. YGR213C, Accession No. YLR346C, Accession No. YIR017C, and Accession No. YLL056C. A second expression control sequence may comprise nucleotides -500 to -1 (*e.g.*, nucleotides -1000 to -1) of a gene selected from the group consisting of Accession No. YGL205W, Accession No. YJL219W, Accession No. YGR287C, and Accession No. YHL012W. In some embodiments, a first and/or second expression control sequence may include promoter fragments larger or smaller than the foregoing examples. Smaller fragments may be desirable where activity of an expression control sequence is attributed to specific domains (*e.g.*, an upstream activating sequence, an upstream repressing sequence, and/or a TATA sequence) of the complete sequence.

According to some embodiments, an organophosphate degrading enzyme may be selected from the group consisting of organophosphorus hydrolase (OPH), phosphotriesterase, OpdA, organophosphorus acid anhydrolase (OPAA), DFPase, and paraoxonase (PON) (Table 15). These enzymes may hydrolyze one or more organophosphate bonds (Tables 16 and 17). An enzyme, in some embodiments, may be intracellular, may be presented at a cell surface, and/or may be secreted. A yeast

biosensor may be permeabilized by application of an external agent (*e.g.*, an alcohol). In some embodiments, a yeast biosensor may include a mutation in an ergosterol biosynthetic gene. In some embodiments, a yeast biosensor may include a defect (*e.g.*, mutation) in (a) cell wall synthesis, maintenance, or degradation, (b) cell
5 membrane synthesis, maintenance, or degradation, (c) cell repair, and/or (d) cell transport (*e.g.*, drug export pump or import pump). For example, a yeast biosensor may include one or more proteins and/or nucleic acid(s) encoding one or more proteins capable of actively importing a chemical agent into the sensor.

The disclosure relates, in part, to a method of identifying a yeast gene that is
10 upregulated by an organophosphate including (a) contacting a yeast with the organophosphate, (b) collecting RNA from the yeast, (c) contacting the RNA with a yeast microarray having feature loci that correspond to yeast genes under conditions that permit hybridization of complementary sequences, (d) comparing a metric of the hybridization at each feature locus with the same metric of hybridization at a
15 corresponding feature locus for RNA from yeast not contacted with the organophosphate, (e) identifying a feature locus where the hybridization metric is higher for the yeast contacted with the organophosphate than the yeast not contacted with the organophosphate, and (f) correlating the identified feature locus with its respective yeast gene.

20 In some embodiments, a yeast biosensor that is sensitive to an organophosphate may be prepared by (a) identifying a yeast gene that is upregulated by an organophosphate, (b) identifying at least one expression control sequence of the identified gene, (c) operably linking a nucleic acid comprising the expression control sequence to a nucleic acid encoding a reporter, and (d) contacting the operably linked
25 nucleic acids with a cell under conditions that permit uptake of the nucleic acids. The operably linked nucleic acids may be comprised in a yeast plasmid or integrated into a locus of a yeast chromosome. A reporter may be selected from the group consisting of enhanced green fluorescent protein, yeast enhanced green fluorescent protein, *Aequorea coerelescens* green fluorescent protein, DsRed monomer, DsRed2, DsRed
30 express, RedStar2, ASRed2, HcRed1, AmCyan1, ZsYellow1, ZsGreen1, and/or AmCyan1, insect luciferase, bacterial luciferase, bacterial bioluminescence, Renilla

luciferase, uroporphyrinogen III methyltransferase, secreted alkaline phosphatase, β -galactosidase, β -glucuronidase, an ice nucleation protein or combinations thereof.

The present disclosure also relates to a method of identifying a yeast gene that is upregulated by an organophosphate hydrolytic product and/or a process of organophosphate hydrolysis. In some embodiments, this method may include (a) contacting a yeast with an organophosphate hydrolytic product, and (b) comparing the transcription profile of a recombinant OPH⁺ yeast with wild-type yeast in the presence of the organophosphate. In some embodiments, this method may include (a) contacting a yeast with the organophosphate hydrolytic product, collecting RNA from the yeast, (b) contacting the RNA with a yeast microarray having feature loci that correspond to yeast genes under conditions that permit hybridization of complementary sequences, (c) comparing a metric of the hybridization at each feature locus with the same metric of hybridization at a corresponding feature locus for RNA from yeast not contacted with the organophosphate hydrolytic product, (d) identifying a feature locus where the hybridization metric is higher for the yeast contacted with the organophosphate hydrolytic product than the yeast not contacted with the organophosphate hydrolytic product, and (e) correlating the identified feature locus with its respective yeast gene. This method may further include confirming differential expression by quantitative reverse transcription PCR.

The present disclosure also relates to a method of identifying a yeast gene that is upregulated by or during organophosphate hydrolysis. In some embodiments, this method may include (a) contacting a recombinant OPH⁺ yeast with an organophosphate under conditions that permit organophosphate hydrolysis, (b) collecting RNA from the recombinant OPH⁺ yeast, (c) contacting the subtracted RNA with a yeast microarray having feature loci that correspond to yeast genes under conditions that permit hybridization of complementary sequences, (d) comparing a metric of the hybridization at each feature locus with the same metric of hybridization at a corresponding feature locus for RNA from yeast lacking OPH contacted with the organophosphate, (e) identifying a feature locus where the hybridization metric is higher for the recombinant OPH⁺ yeast contacted with the organophosphate than the yeast lacking OPH contacted with the organophosphate, and (f) correlating the

identified feature locus with its respective yeast gene. This method may further include confirming differential expression by quantitative reverse transcription PCR.

A yeast biosensor that is sensitive to an organophosphate hydrolytic product and/or organophosphate hydrolysis, according to some embodiments, may be prepared by (a) identifying a yeast gene that is upregulated by an organophosphate hydrolytic product, (b) identifying at least one expression control sequence of the identified gene, (c) operably linking a nucleic acid comprising the expression control sequence to a nucleic acid encoding a reporter, and (d) contacting the operably linked nucleic acids with a cell under conditions that permit uptake of the nucleic acids. The operably linked nucleic acids may be comprised in a yeast plasmid or integrated into a locus of a yeast chromosome. A reporter may be selected from the group consisting of enhanced green fluorescent protein, yeast enhanced green fluorescent protein, *Aequorea coerulescens* green fluorescent protein, DsRed monomer, DsRed2, DsRed express, RedStar2, ASRed2, HcRed1, AmCyan1, ZsYellow1, ZsGreen1, and/or AmCyan1, insect luciferase, bacterial luciferase, bacterial bioluminescence, Renilla luciferase, uroporphyrinogen III methyltransferase, secreted alkaline phosphatase, β -galactosidase, β -glucuronidase, an ice nucleation protein or combinations thereof.

A yeast biosensor that is sensitive to both an organophosphate and an organophosphate hydrolytic product may be prepared by (a) identifying a yeast gene that is upregulated by an organophosphate, (b) identifying at least one expression control sequence of the identified organophosphate-sensitive gene, (c) operably linking a nucleic acid comprising the organophosphate expression control sequence to a nucleic acid encoding a reporter, (d) contacting the operably linked organophosphate nucleic acids with a cell under conditions that permit uptake of the nucleic acids, (e) identifying a yeast gene that is upregulated by an organophosphate hydrolytic product and/or by a process of organophosphate hydrolysis, (f) identifying at least one expression control sequence of the identified organophosphate hydrolysis-sensitive gene, (g) operably linking a nucleic acid comprising the organophosphate hydrolytic product expression control sequence to a nucleic acid encoding a reporter, and (h) contacting the operably linked organophosphate hydrolytic product nucleic acids with a cell under conditions that permit uptake of the nucleic acids. The operably linked organophosphate nucleic acids and/or the operably linked

organophosphate hydrolytic product nucleic acids may be comprised in one or more plasmids or integrated into a yeast chromosome. An expression control sequence may include a promoter. In some embodiments, an expression control sequence may include nucleotides -500 to -1 of the identified gene. A reporter may be selected from the group consisting of enhanced green fluorescent protein, yeast enhanced green fluorescent protein, *Aequorea coerelescens* green fluorescent protein, DsRed monomer, DsRed2, DsRed express, RedStar2, ASRed2, HcRed1, AmCyan1, ZsYellow1, ZsGreen1, and/or AmCyan1, insect luciferase, bacterial luciferase, bacterial bioluminescence, Renilla luciferase, uroporphyrinogen III methyltransferase, secreted alkaline phosphatase, β -galactosidase, β -glucuronidase, an ice nucleation protein or combinations thereof.

BRIEF DESCRIPTION OF THE DRAWINGS

Some specific example embodiments of the disclosure may be understood by referring, in part, to the following description and the accompanying drawings, wherein:

FIGURE 1 is an image of a gel illustrating PCR amplification of the *opd* gene (M, λ HindIII DNA marker; lane 1, negative PCR control; lane 2, *opd* PCR product);

FIGURE 2 is an image of a gel illustrating a diagnostic restriction digest (*Hind*III/*Bam*HI) of pOPD-ESC-URA produced the fragments 1031 and 6554 bp (far right lane) to confirm cloning the *opd* gene into the yeast pESC-URA plasmid;

FIGURE 3 is a sketch of a yeast *opd* expression plasmid having the yeast 2 μ origin for plasmid replication, the *URA3* auxotrophic marker for yeast transformant selection, the yeast pGAL1 promoter for regulated expression, the bacterial *opd* gene, and the yeast TCYC1 terminator for transcriptional termination;

FIGURE 4A illustrates a DNA sequence of a yeast codon-optimized *opd* gene (SEQ ID NO: 1);

FIGURE 4B illustrates a DNA sequence of a yeast codon-optimized DsRed express gene (SEQ ID NO: 2);

FIGURE 5 is an image of gels illustrating yeast transformants expressing *opd*, wherein (i) pESC-URA (control plasmid) and pOPD-ESC-URA were transformed into *S. cerevisiae* W3031A, (ii) RNA was prepared, (iii) RT-PCR was used to

examine *opd* mRNA expression, and (iv) actin was used as an internal loading control (Dex, dextrose; Gal, galactose);

FIGURE 6 is a chart illustrating growth (monitored at A_{600}) of *S. cerevisiae* harboring control (pESC-URA) or test (pOPD-ESC-URA) plasmids under repressed
5 (dex, dextrose) or inducing (gal, galactose) conditions.

FIGURE 7A is a chart illustrating dose-dependent inhibition of *S. cerevisiae* BY4741 growth (monitored at A_{600}) in the presence of paraoxon;

FIGURE 7B is a chart illustrating growth of *S. cerevisiae* W3031A wild-type (pESC-URA) and recombinant OPH⁺ cells (monitored at A_{600}) in the presence of 1
10 mM paraoxon;

FIGURE 8 is a chart illustrating growth (monitored at A_{600}) of *S. cerevisiae* harboring pOPD-ESC-URA in the presence of varying ethanol concentrations (2-8%);

FIGURE 9A is a chart illustrating the effect of 0.5 mM paraoxon on the growth (monitored at A_{600}) of *S. cerevisiae* wild-type (BY4741) and the membrane
15 mutant strain *erg3*;

FIGURE 9B is a chart illustrating the effect of 0.5 mM paraoxon on the growth (monitored at A_{600}) of *S. cerevisiae* wild-type (BY4741) and the membrane mutant strain *erg4*;

FIGURE 9C is a chart illustrating the effect of 0.5 mM paraoxon on the growth (monitored at A_{600}) of *S. cerevisiae* wild-type (BY4741) and the membrane
20 mutant strain *erg6*;

FIGURE 10A is a chart illustrating the effect of 500, 250, and 125 μ M paraoxon (para) on the growth of *S. cerevisiae* wild-type (BY4741);

FIGURE 10B is a chart illustrating the effect of 500, 250, and 125 μ M paraoxon (para) on the growth of *S. cerevisiae* membrane mutant strain *erg6*;
25

FIGURE 11 is an image of gels illustrating expression of paraoxon-inducible genes (monitored by relative RT-PCR) in which RNA was prepared from wild-type or recombinant yeast incubated in the absence or presence of 3 mM paraoxon for 60 min (C, wild-type without paraoxon; CP, wild-type with paraoxon; recombinant without
30 paraoxon (T); recombinant with paraoxon (TP));

FIGURE 12 is an image of gels illustrating gene expression (monitored by relative RT-PCR) of wild-type yeast incubated with varying concentrations of paraoxon for 60 min;

FIGURE 13 is an image of gels illustrating dose response changes in gene expression monitored by relative and real-time RT-PCR in which RNA was prepared from wild-type yeast incubated with varying concentrations of paraoxon for 60 min.;

FIGURE 14 is an image of gels illustrating a time course of YGR035C and YLR346C induction monitored by relative and real-time RT-PCR in which RNA was prepared from wild-type yeast incubated with 2.5 mM paraoxon;

FIGURE 15A illustrates a DNA sequence of YGR035C-FI-YeGFP (SEQ ID NO: 3);

FIGURE 15B illustrates a DNA sequence of pYLR346C-FI-YeGFP (SEQ ID NO: 4);

FIGURE 16 is a chart illustrating a time course of YeGFP induction in *S. cerevisiae* in the presence of 3 mM paraoxon and harboring either pYGR035C-FI-YeGFP or pYLR346C-FI-YeGFP;

FIGURE 17 is a chart illustrating a dose response of YeGFP-induction in *S. cerevisiae* harboring pYLR346C-FI-YeGFP in the presence of 0.1 to 3.0 mM paraoxon for 120 min.;

FIGURE 18A illustrates a DNA sequence of pYGR287C-FI-YDsRed (SEQ ID NO: 5);

FIGURE 18B illustrates a DNA sequence of pPOX1-FI-YDsRed (SEQ ID NO: 6);

FIGURE 19 is a chart illustrating a time course of YDsRed induction in recombinant OPH⁺ yeast harboring pPOX1-F2-YDsRed in the presence of 3 mM paraoxon; and

FIGURE 20 is a chart illustrating a dose response of YDsRed-induction in *S. cerevisiae* OPH⁺ harboring pPOX1-F2-YDsRed in the presence of 0.1 to 3.0 mM paraoxon for 255 min.

DETAILED DESCRIPTION

Current methodologies for the detection of nerve gas agents include ion mobility spectrometry, electrochemical sensors, gas/liquid chromatography, mass spectrometry, infrared spectroscopy, photo ionization detectors, surface acoustic wave sensors, and color-change chemistry. These methods may be generally laborious, and may require expensive laboratory equipment and complicated methodology. Methods used for the hydrolysis of nerve gases and OP pesticides include chemical and enzymatic hydrolysis using naturally occurring enzymes derived from bacteria, mammals, squid, clams, and protozoa. Drawbacks of using a purified enzyme may include a need for tedious and/or expensive isolation/preparation methods and instability of the purified enzyme.

In some embodiments, a biosensor may include a microbe (*e.g.*, a bacteria or a yeast). For example, a whole cell bacterial biocatalyst heterologously expressing the *opd* (organophosphate degrading) gene may be prepared that hydrolyze organophosphate compounds. In some cases, attention must be given to the cellular location of the enzyme since this may influence reaction rates. For example, OPH expressed on the cell surface may more effectively hydrolyze OP compounds than whole cell biocatalysts where OPH resides within the cytoplasm. Without limiting any embodiment of the disclosure to any particular mechanism of action, this may relate to the permeability barrier function of the bacterial cell envelope. Permeabilizing the outer membrane using solvents, freeze/thaw methods, and/or using outer membrane permeable mutants may, in some embodiments, reduce these issues and increase the rate of passive diffusion and hydrolysis rates.

In some embodiments, a yeast biosensor may include a dual reporter system capable of detecting (a) an organophosphate compound and (b) hydrolysis of the organophosphate, for example, by detecting a degradation product of the organophosphate. A yeast biosensor may further include a biochemical system for degrading an organophosphate compound. Yeast may be genetically engineered to be able to biodegrade chemical agent contamination by expressing heterologous enzymes that biodegrade these agents, and also be engineered to detect the chemical agents and its biodegraded products using differentially inducible promoter/fluorescent protein fusions. According to some embodiments, the ability to modify, degrade, and/or

detoxify a chemical agent may provide the sensor with a self-clearing or auto-reset feature. In other embodiments, this ability may allow a biosensor to be used not only to detect a chemical agent, but also to clear that agent from a space.

The yeast, *S. cerevisiae*, may be used in some embodiments of the disclosure because (i) it is resistant to environmental extremes; (ii) it is genetically well defined with a plethora of mutants available through the *Saccharomyces* Genome Deletion Project (Stanford); (iii) it may be used for the expression of heterologous proteins including the organophosphoric acid anhydrolase encoding gene; (iv) it is non-pathogenic; (v) it is readily lyophilized and has good survival rates after 10 years of storage, and (vi) yeast genotoxic-inducible genes respond to a broader spectrum of damaging agents than some bacteria. This may be important for the identification of genes, which may be induced by different OP agents.

In some embodiments, a biosensor may benefit from the relatively rapid doubling time of bacteria (e.g., 20 minutes compared to 70 minutes for yeast). In other embodiments, slower growth is tolerated in view of, for example, the ability of large substrates to enter the yeast cell such as OP pesticides (e.g. azinphos-methyl, diazinone, dimethoate, pirimiphos-methyl) and the availability of specific mutants to increase substrate permeability. In addition, yeast biosensor production may occur in a laboratory where time is not a major constraint.

In a specific embodiment, the *Flavobacterium* sp. */Pseudomonas diminuta* OPH encoding gene may be heterologously expressed in *S. cerevisiae* to create a yeast biocatalyst capable of hydrolyzing one or more OP compounds, such as VX or the VX model simulant, paraoxon. To maximize substrate entry into the cell, a *S. cerevisiae* cell wall mutant strain, which exhibits increased porosity and allows the passive diffusion of large molecules, may be used. For example, the mutant strain (*MATa his3D1 leu2DO met15DO ura3DO DSMII*)(ATCC4005882) has been deleted for *SMII* (also known as *KNR4*), a gene involved in (1,3)- β -glucan synthesis and chitin synthase expression, which are major components of the yeast cell wall. The *SMII* deletion results in a reduction in overall (1,3)- β -glucan content, a reduction in (1,3)- β -glucan synthase activity, and an increase in cell wall chitin content. The mutant is more sensitive to SDS, suggesting that the cell wall has become weakened. Cell permeability assays have shown that the mutant is more permeable to substrates

than the wild-type strain. The ability of a yeast biocatalyst to hydrolyze OP compounds may be tested using VX or a VX simulant such as paraoxon.

A rate-limiting step in the hydrolysis of substrates using whole cell bacterial biocatalysts may be entry of the compound into the cell. Accordingly, the efficiency of bacterial catalysts may be significantly improved by the use of permeable mutants which allow the substrate to more efficiently enter the cell via passive diffusion. Although OP substrates can enter yeast by non-specific mechanisms, a yeast mutant that displays increased permeability may be used. The *Saccharomyces* genome deletion project, which has successfully deleted 95% of the 6,200 open reading frames (ORFs), has provided a wealth of information to the researcher. If required, other yeast mutant strains may be readily available and may be analyzed for the ability of OP substrates to gain entry into the cell.

Preliminary results indicated that intact yeast cells are able to act as intact biocatalysts and hydrolyze the model substrate paraoxon. Nevertheless, specific experiments indicated that the yeast cell membrane limited paraoxon entry and therefore acted as a permeability barrier. Treatment of yeast cells with a permeabolization agent such as digitonin increased yeast paraoxon hydrolysis 3 to 4-fold. This suggested that disrupting the yeast cell membrane increased the rate of paraoxon into the cell and thereby increased yeast biocatalytic activity. In addition, an *erg6* mutant, which has a specific defect in ergosterol (membrane) biosynthesis, was hypersensitive to paraoxon. This suggests that membrane defects increase substrate permeability and alters the rate of paraoxon entry. Therefore, in some embodiments, yeast mutants such as those that harbor mutations in ergosterol biosynthesis such as the *erg6* mutation may be used to increase membrane permeability to different substrates (Gaber RF et al., (1989) Mol Cell Biol 9, 3447-56; Hemenway CS & Heitman J (1996) J Biol Chem 271, 18527-34). In another embodiment, the yeast (or host species of choice) may be specifically engineered to express an active OP/chemical agent membrane transporter to actively uptake the chemical agent in order to increase the concentration of the chemical agent inside the cell.

The interaction of OPH with the OP substrate may also be influenced by the rate of active export of the agent, which is mediated by specific efflux pumps. For

example, 22 yeast genes encoding putative ABC transporter proteins, which are involved in the active efflux of a wide range of drugs and compounds, have been identified (Rogers B et al., (2001) J Mol Microbiol Biotechnol 3, 201-214). The three major transporters are PDR5 (pleiotropic drug resistance), YOR1 (yeast oligomycin resistance) and SNQ2 (sensitivity to 4-nitroquinolin-N-oxide). In some embodiments, a yeast biosensor may include a drug efflux mutation alone or in combination with a yeast permeability mutation(s) and/or a mutation(s) that increases sensitivity of the cell to the chemical agent, for example, to increase the interaction of the substrate with intracellular enzyme.

The OPH enzyme may be secreted or presented at the cell surface to bypass a substrate entry and/or efflux limitation according to some embodiments. A similar strategy has been employed for bacterial whole cell catalysts. Fusion of the OPH enzyme to the ice-nucleation protein was shown to target the OPH enzyme to the cell surface where it was displayed and efficiently catalyzed OP agents (Mulchandani A et al., (1999) Biotechnol Bioeng 63, 216-23; Shimazu M et al., (2003) Biotechnol Prog 19, 1612-4; Mulchandani P et al., (2001) Biosens Bioelectron 16, 433-7). Protein secretion in yeast may be mediated by fusion of a synthetic leader peptide, which contains the necessary signals to direct the protein through the secretory pathway (Parekh R et al., (1995) Protein Expr Purif 6, 537-45). Fusion of the leader peptide to the bovine pancreatic trypsin inhibitor (BPTI) enabled secretion of 140 µg/ml of active BPTI (Parekh RN et al., (1996) Biotechnol Prog 12, 16-21). Likewise, in some embodiments, the OPH enzyme may include a leader peptide with secretory pathway signals. Export of the OPH enzyme may be desired where a yeast is less permeable to a parent compound than one or more hydrolytic products of the parent compound.

While rates of hydrolysis by OPH may vary, in some embodiments, enzymes that exhibit higher catalytic activity towards different chemical agents may be used. In addition, different formulations of yeast biocatalysts may be combined each expressing different forms of the OPH enzyme to provide optimal substrate specificity for the particular OP target.

In some embodiments, *S. cerevisiae* genes transcriptionally induced by VX (or paraoxon) and genes, which are induced by the hydrolysis products may be identified. For example, global transcription profiling (microarray analysis) may be performed

on *S. cerevisiae* *SMII* in the presence or absence of a chemical agent such as VX and on recombinant *S. cerevisiae* *SMII* expressing OPH in the presence or absence of VX. The comparison between wild-type cells incubated with VX, and recombinant cells expressing OPH incubated with VX, may facilitate identification of one or more yeast genes induced by the hydrolysis of VX. Hydrolysis of VX using a yeast strain
5 expressing OPH may result in a transcriptional profile that is distinct from cells lacking the ability to hydrolyze VX. Real-time RT-PCR may then be used on prioritized targets using different concentrations of VX to identify yeast genes that are induced at low concentrations and in a dose-dependent manner.

- 10 Promoter regions of prioritized genes may be mapped using the *Saccharomyces* promoter database (SCPD) (maintained by Cold Spring Harbor Laboratories, Cold Spring Harbor, NY), literature analysis, and/or 5' promoter analysis. Such mapping may aid identification of one or more promoter regions that confer sensitivity to VX, VX hydrolytic products, and/or a process of VX hydrolysis.
- 15 Promoters may be cloned, fused to enhanced green fluorescent protein (EGFP) or DsRed express (Clontech), which exhibit distinct spectral properties, to create a dual reporter yeast biosensor that differentially fluoresces during VX contamination detection and biodegradation. In some embodiments, single promoter-reporter fusions may successfully detect genotoxic agents. In other embodiments, a signature
20 of promoter-reporter fusions may be required to differentiate OP agents.

- In some embodiments, a detection system may include a bioluminescence component (*e.g.*, *luxAB*). Bioluminescence may be a transient signal. For example, LuxAB proteins may be sensitive to elevated temperature (30°C) and may also require additional substrates for activity. In some embodiments, a detection system may
25 include a fluorescence component (*e.g.*, a fluorescent protein). Fluorescent proteins for use in a detection system may be stable and may have one or more of a variety of spectral properties. A biosensor, according to some embodiment, may be configured with a detection system (*e.g.*, fluorescence) suitable for use outside of the laboratory under harsh conditions.

- 30 In some embodiments, a biosensor may be self-contained, may require no exogenous substrates and/or consumables, may be inexpensive to produce in bulk

quantities, and/or may be visually identified using a simple hand-held illumination device.

In some embodiments, a biosensor may be used for the detection and biodegradation of organophosphate nerve agents and pesticides such as VX, soman, sarin, demeton S, paraoxon, tabun, DFP, acephate, chlorpyrifos, coumaphos, coroxon, parathion, diazinon, and dMUP.

However, by changing an enzyme's substrate specificity by using mutant enzymes (by error prone PCR or by directed evolution such as DNA shuffling) or natural enzymes which are capable of biodegrading different chemical agents, embodiments of the disclosure may be used to achieve broader specificity to detect and biodegrade other targets such as H-class agents (*e.g.*, mustard gas).

OPH hydrolyzes, and thereby reduces the toxicity of a wide variety of OP pesticides and chemical warfare agents by cleaving the P-O, P-F, and P-S containing bonds; however, OPH cleaves these bonds with different efficiencies. For example, OPH catalyses: the P-O bond of paraoxon, parathion, and coumaphos with k_{cats} of 67-5,000 s^{-1} ; the P-F bond of diisopropyl fluorophosphate (DFP), sarin, and soman with k_{cats} of 0.01-500 s^{-1} ; and the P-S bond of VX, demeton-S, malathion, and acephate with k_{cats} of 0.0067-167 s^{-1} . Therefore, the hydrolytic efficiency of OPH towards P-S bonds is lower; VX, for example, is cleaved at an efficiency which is 1000-fold less than paraoxon. In order to improve the catalytic efficiency and specificity of OPH, OPH variants have been generated by designed and random approaches (Watkins LM et al., (1997) J Biol Chem 272, 25596-601; Yang H et al., (2003) Protein Eng 16, 135-45; Cho CM et al., (2002) Appl Environ Microbiol 68, 2026-30; Chen-Goodspeed M et al., (2001) Biochemistry 40, 1325-31). Both approaches rely on mutagenesis of the *opd* gene followed by screening against the target of choice in order to optimize the mutant enzyme for the specific target. These studies have shown that the efficiency of the reaction can be increased by 3 orders of magnitude using 'difficult to cleave' substrates (Hill CM et al., (2003) J Am Chem Soc 125, 8990-1; Cho CM et al., (2004) Appl Environ Microbiol 70, 4681-5). Moreover, the hydrolytic activities of the variants were comparable to those obtained with the most efficiently hydrolyzed substrate paraoxon. This indicates that by rational and random changes in the OPH sequence, efficient enzymes can be generated that target poorly hydrolyzed substrates.

Intact recombinant OPH⁺ yeast cells may hydrolyze paraoxon. In some embodiments, in order to improve the efficiency of the OPH enzyme, designed and randomized mutagenesis of OPH may be performed. For example, by screening a combination of designed and random amino acid changes in the enzyme active site, followed by random directed evolution (DNA shuffling) against specific organophosphates, OPH variants may be isolated with significantly improved catalytic efficiency towards the OP agent. Three dimensional structure analysis of OPH using a broad substrate analog has identified three distinct binding pockets within the active site of the enzyme; these binding sites have been termed the small subsite (defined by the side chains of Gly-60, Ile-106, Leu-303, Ser-308, Cys-59, and Ser-61), the large subsite (His-254, His-257, Leu-271, and Met-317) and the leaving group subsite (Trp-131, Phe-132, Phe-306, and Tyr-309) (Vanhooke JL et al., (1996) Biochemistry 35, 6020-5). Amino acid changes in these subsites dramatically alter the stereoselectivity and reactivity of OPH (Chen-Goodspeed M et al., (2001) Biochemistry 40, 1325-31). For example, randomization of amino acid residues in the active site (Ile-106, Try-131, Phe-132, Ser-308 and Tyr-309) increased OPH activity against the already efficiently hydrolyzed substrate paraoxon by 63-fold (Griffiths AD & Tawfik DS (2003) Embo J 22, 24-35). Similarly, Hill *et al.* (Hill CM et al., (2003) J Am Chem Soc 125, 8990-1) increased OPH catalytic activity against a soman analog by three orders of magnitude simply by changing 3 amino acids (His-254, His-257 and Leu-303 to glycine, tryptophan, and threonine, respectively). The latter studies relied on random changes in the amino acids followed by global screening against the OP substrate of choice.

Directed evolution or DNA shuffling may also be used to screen the entire protein sequence to find an enzyme with increased fitness (Stemmer WP (1994) Proc Natl Acad Sci 91, 10747-51; Stemmer WP (1994) Nature 370, 389-91). This process of recombination and mutation, performed by random fragmentation of a pool of single or related genes, followed by reassembly of the fragments by primerless PCR, has improved the activities of green fluorescence protein, β -galactosidase, and β -lactamase by 45-, 1,000- and 32,000-fold, respectively (Zhang JH et al., (1997) Proc Natl Acad Sci 94, 4504-9; Crameri A et al., (1996) Nat Biotechnol 14, 315-9). DNA shuffling has also proven to be successful in increasing the catalytic activity of OPH

(Yang H et al., (2003) Protein Eng 16, 135-45; Cho CM et al., (2002) Appl Environ Microbiol 68, 2026-30). In particular, DNA shuffling against the pesticide chloropyrifos, which is hydrolyzed by the wild-type enzyme almost 1000-fold slower than the preferred substrate paraoxon, resulted in a 725-fold increase in the k_{cat}/K_m value (Cho CM et al., (2004) Appl Environ Microbiol 70, 4681-5).

In some embodiments, the *Flavobacterium* spp. *opd* gene may be shuffled with a related gene encoding an organophosphorus hydrolase or similar hydrolyzing enzyme from a different species. For example, the *Flavobacterium* spp. *opd* gene may be shuffled with a closely related *Agrobacterium radiobacter opdA* gene (Horne I et al., (2002) Appl Environ Microbiol 68, 3371-6) to 'accelerate' directed evolution. Shuffling of closely related genes can increase the potential of improved variants compared to shuffling of a single gene (Cramer A et al., (1998) Nature 391, 288-91). The *opdA* gene is approximately 88% identical to *opd* at the nucleotide level and has been shown to have a broader substrate range and superior kinetics for some substrates (notably demeton-S) than *opd*.

According to some embodiments, an efficient yeast biocatalyst/biosensor may function outside a laboratory. In some of these embodiments, a biosensor may: (i) use optimal expression signals in order to achieve high level expression; (ii) integrate multiple copies of the *opd* gene/reporter genes into the yeast genome which, in turn, lead to greater expression, and/or (iii) stably maintains the *opd* gene/reporter genes even in the absence of selective pressure. The Examples of the disclosure relate to episomal expression of the OPH protein and the fluorescent reporter plasmids from a yeast 2 μ plasmid. This strategy may provide a simplistic and common approach for the heterologous expression of foreign genes. The 2 μ plasmid may have low segregational stability, *i.e.*, the plasmid may not be stably maintained in a yeast population (Murray AW & Szostak JW (1983) Cell 34, 961-70). This may result in a heterogeneous yeast population even under selective pressure. For example, preliminary results indicated that only approximately 25% of yeast cells stably maintained the OPH expression vector under selective pressure. This means that most of the yeast cells did not contain the OPH plasmid and therefore, may have been operating under suboptimal conditions.

Episomal plasmid instability may be overcome, in some embodiments, by integrating the plasmid/gene of interest into the yeast genome. This results in a stable, clonal yeast population that maintains the inserted DNA sequence for many generations even in the absence of selective pressure (Lopes TS et al., (1989) Gene 5 79, 199-206; Parekh RN et al., (1996) Biotechnol Prog 12, 16-21). Integrated sequences may be maintained at a lower copy number (1-5) compared to episomal plasmids (30-50) (Orr-Weaver TL & Szostak JW (1983) Mol Cell Biol 3, 747-9); however, since the number of integrated copies is proportional to the number of target sites in the yeast genome (Wilson JH et al., (1994) Proc Natl Acad Sci 91, 177-81), 10 yeast cells carrying multiple copies of the integrated DNA may be generated when the insertion sequence is present in multiple copies. For example, ribosomal DNA (rDNA) encompasses about 140 copies of a 9.1 kb unit repeated in tandem on chromosome XII (Petes TD (1979) Proc Natl Acad Sci 76, 410-4). By targeting the rDNA locus, phosphoglycerate kinase (PGK) was integrated at 100-200 copies per 15 cell, and when expressed from the glyceraldehydes-3-phosphate dehydrogenase (GAPDH) promoter, represented approximately 50% of the total soluble protein. Similarly, by targeting the Ty δ sequences for homologous recombination, which are present at about 150-200 copies per cell, up to 30 copies of the integrated sequence may be obtained. In comparison to using 2 μ plasmids, 2 to 10-fold increases in 20 protein expression may be achieved. Therefore, in some embodiments, the *opd* gene/reporter genes may be integrated into the yeast genome to create a stable yeast biocatalyst/biosensor.

The *opd* gene, which was originally derived from the bacterium *Flavobacterium* spp., may contain codons that are rarely used in yeast (or the specific 25 host strain) or contain expression-limiting regulatory elements within the coding sequence. In some embodiments, the OPH encoding *opd* gene, may be codon optimized to ensure efficient expression in yeast/the particular host species. The reporter genes may also be modified to ensure optimal codon recognition and to remove expression limiting regulatory elements to ensure efficient expression in the 30 host species of choice. (For example, the sequences of the codon optimized *opd* and YDsRed genes are provided in **Figures 4A and 4B**).

A pGAL regulatable promoter was used in Examples of the disclosure to drive expression of the foreign *opd* gene since expression could be repressed or induced by the presence of dextrose or galactose, respectively. However, a promoter that is constitutively and strongly expressed may be used to express of *opd* gene. For example, the glyceraldehyde phosphate dehydrogenase (GAPDH) promoter is routinely used to achieve high level, foreign gene expression in *S. cerevisiae* since it is both strongly and constitutively expressed (Edens L et al., (1984) Cell 37, 629-33; Imamura T et al., (1987) J Virol 61, 3543-9). Therefore, in some embodiments, the GAPDH promoter or a similarly highly expressed constitutive promoter may be used to drive foreign gene expression in yeast. For example, the GAPDH promoter may be operably linked (*e.g.*, positioned adjacent to) the *opd* gene such that the *opd* gene is constitutively expressed.

Microarray analysis may be used in some embodiments to identify genes that are sensitive to paraoxon and the paraoxon hydrolysis products. As illustrated by the Examples of the disclosure, microarray analysis identified approximately 1900 paraoxon-inducible genes and genes which were associated with paraoxon hydrolysis. Therefore, microarray analysis may be used to identify genes and the corresponding promoters that are sensitive to other organophosphates or other chemical agents. Microarray analysis may also be used to identify genes and the corresponding promoters that are sensitive to the degradation products of the other organophosphates or chemical agents.

Global transcription profiling (microarray analysis) may be performed on wild-type *S. cerevisiae* (or the species of choice) in the presence or absence of the chemical agent, and on recombinant *S. cerevisiae* expressing an enzyme/metabolizing agent that may hydrolyze the chemical agent in the presence or absence of the chemical agent. In another embodiment, an alternative approach for identifying genes which are induced by the hydrolysis of the chemical agent is to incubate the cells directly with the hydrolysis products rather than relying on cells to hydrolyze the agent. For example, enzymatic hydrolysis of the OP nerve agent VX produces 2-(diisopropyl)aminoethanethiol (Bonierbale E et al., (1997) J Chromatogr B Biomed Sci Appl 688, 255-64; Joshi KA et al., (2006) Anal Chem 78, 331-6). Microarray

analysis may be performed using RNA prepared from cells incubated in the presence of 2-(diisopropyl)aminoethanethiol hydrochloride.

A similar approach may be used, in some embodiments, to identify genes which are transiently-induced by the hydrolyzed products. Transiently-induced genes may be desirable to allow the progress of a decontamination process to be monitored. Cells may be exposed to the hydrolyzed products for 60 min, divided equally, and either used for RNA preparations, or washed, and resuspended in medium lacking the hydrolyzed products. Genes, which are initially induced by the metabolites, but subsequently return to the basal uninduced level, are transiently-induced genes.

In another embodiment, 'light' (bioluminescent) genes which emit light at distinct, different wavelengths may be used as the reporter signal. For example, the *Vibrio harveyi luxAB* genes may be used in yeast (Szittner R et al., (2003) Biochem Biophys Res Commun 309, 66-70). LuxAB-yeast cells are viable in the presence of 0.5% Z-9 tetradecenal and produce a bioluminescent signal similar to that obtained with n-decanal. Moreover, the bioluminescent signal remains strong for 24 h without further addition of the aldehyde substrate. Coexpression of the oxidoreductase *Vibrio harveyi* gene (*frp*) which encodes for the limiting substrate FMNH₂, further enhanced the bioluminescent signal to levels comparable to prokaryotic systems. These experiments resulted in a bioluminescent signal approaching 9x10⁵-fold above background levels (Gupta RK et al., (2003) Fems Yeast Res 4, 305-13). A 'transient' luminescent signal may permit temporal monitoring of the decontamination process.

A potential disadvantage of luminescence is the thermal instability at elevated temperatures (Escher A et al., (1989) Proc Natl Acad Sci 86, 6528-32). However, the thermally stable LuxAB from *Xenorhabdus luminescens* may be used if required or desired. Luciferase activity from *X. luminescens* displays a high thermal stability (half life of 3 h at 45°C) and may be the bioluminescent system of choice for biosensors used at higher temperatures. In addition, a 'signature' of promoters fused to different luciferases with different emission colors (Lin LY et al., (2004) Biochemistry 43, 3183-94) may be used to monitor the decontamination process over an extended period of time.

In another embodiment, rather than biodegrading the chemical agent and directly reducing the toxicity of the chemical agent, the biocatalyst may modify the chemical agent to render it more susceptible to chemical hydrolysis.

5 In another embodiment, the biocatalyst may harbor multiple biodegrading enzymes and multiple promoter reporter gene fusions in order to detect and biodegrade different chemical agents.

10 In another embodiment, clonal cells, each harboring a specific biodegrading enzyme and specific reporter detection system for a specific chemical, may be mixed into a heterogeneous population that as a group, can detect and biodegrade different chemical agents.

In another embodiment, the chemical agent may be hydrolyzed or biodegraded using a molecule with hydrolyzing capability (other than an enzyme) such as a deoxyribonucleic acid (*e.g.*, DNAzyme) or ribonucleic acid, or similar which can be produced in a living cell.

15 As will be understood by those skilled in the art, other equivalent or alternative systems, devices, and methods for detecting and/or modifying chemical agents, according to embodiments of the present disclosure can be envisioned without departing from the essential characteristics thereof. For example, devices of the disclosure may be manufactured in either a handheld or a tabletop configuration, and
20 may be operated sporadically, intermittently, and/or continuously. In addition, a biosensor may be configured for use under one or more temperatures and/or pressures. Moreover, individuals of ordinary skill in the art would recognize that there a number of autologous and heterologous nucleic acids may be used to detect and/or modify a target chemical. Also, the disclosure is not limited to any particular
25 light sources and/or light emission optics, but broadly contemplates the use of any type of emitter that may be appropriately tuned to the desired wavelength(s). Similarly, the disclosure contemplates the use of any type of light detector and/or light detection optics. All or part of a system of the disclosure may be configured to be disposable and/or reusable. From time to time, it may be desirable to clean, repair,
30 and/or refurbish a reusable component. Moreover, one of ordinary skill in the art will appreciate that no embodiment, use, and/or advantage is intended to universally control or exclude other embodiments, uses, and/or advantages. These equivalents

and alternatives along with obvious changes and modifications are intended to be included within the scope of the present disclosure. Accordingly, the foregoing disclosure is intended to be illustrative, but not limiting, of the scope of the disclosure as illustrated by the following claims.

5

EXAMPLES

Some embodiments of the disclosure may be illustrated by one or more of the following examples.

Examples 1-9 elaborate construction of a yeast expression vector containing the bacterial *opd* gene and transformation into *S. cerevisiae*. Reverse transcription-PCR was used to confirm that the *opd* gene was expressed in yeast. Paraoxonase assays using enzyme lysates prepared from the recombinant OPH⁺ yeast indicated the *opd* gene produced functional OPH protein that hydrolyzed paraoxon. Intact whole cell paraoxonase assays indicated that yeast cells could hydrolyze paraoxon and function as a biocatalyst. Yeast colony counting onto selective and non-selective media indicated that the yeast episomal plasmid expressing OPH was not stably maintained by the yeast population. This indicates that for optimal yeast biocatalyst function, the *opd* gene may be integrated into the yeast genome to create a stable, clonal yeast population. Testing and optimization studies were performed which demonstrated that: (i) disruption of the yeast membrane increased whole cell paraoxon hydrolysis; (ii) pretreatment with low concentrations of ethanol increased whole cell activity, and (iii) the *erg6* yeast membrane mutant was hypersensitive to paraoxon, suggesting that an *erg6* mutation, increased the rate of paraoxon entry.

Examples 10-12 elaborate identification of *S. cerevisiae* genes transcriptionally induced by paraoxon, a process of paraoxon hydrolysis, and/or products of paraoxon hydrolysis. Microarray analysis was used to identify yeast genes induced by paraoxon and genes which were induced by paraoxon hydrolysis. A large number of paraoxon-inducible genes were identified which were significantly and substantially induced. The paraoxon-inducible genes YLR346C and YGR035C were prioritized for further analysis and quantitative real-time PCR demonstrated that both of these genes were quickly (7.5 min) and sensitively induced by paraoxon. Therefore, YLR346C and YGR035C displayed the desired characteristics for incorporation into

the biosensor and were prioritized for Examples 13-14. Microarray analysis also identified 33 genes which were induced at least 2-fold following paraoxon hydrolysis. Real-time PCR verified that 2 of these genes (POX1 and YGR287C) were only induced in OPH⁺ strains in the presence of paraoxon. Therefore, POX1 and YGR287C were also prioritized for Examples 13-14. The experiments supporting each of these findings are described in the text below.

Examples 13-14 elaborate construction of an example embodiment of a fluorescent yeast biosensor. Yeast codon optimized YeGFP and YDsRed reporter vectors were constructed. Two paraoxon-inducible promoters (YLR346C and pYGR035C) were fused to YeGFP and 2 promoters associated with paraoxon hydrolysis (POX1 and YGR287C) were fused to YDsRed. The yeast biosensor harboring the YLR346C-YeGFP demonstrated up to 5-fold YeGFP induction in the presence of paraoxon. Moreover, the biosensor was quickly induced (2-fold after 15 min exposure) and induced in a dose-dependent manner by paraoxon. Recombinant OPH⁺ yeast harboring a paraoxon hydrolysis promoter (POX1) fused to YDsRed also displayed induced fluorescence in the presence of paraoxon. YDsRed induction occurred only in yeast strains expressing OPH, indicating induction required both OPH and paraoxon. This suggests that YDsRed induction was strictly associated with paraoxon hydrolysis. YDsRed was induced in a dose-dependent manner by paraoxon suggesting the biosensor responded to the amount of paraoxon hydrolyzed. The experiments supporting each of these findings are described in detail below.

Example 1: Yeast *opd* expression plasmid and *opd* mRNA expression in *S. cerevisiae*.

A yeast expression plasmid containing the *opd* gene under the transcriptional control of the yeast GAL1 promoter, and a yeast ribosome binding site was constructed. A yeast codon optimized *opd* expression plasmid was simultaneously constructed. The *opd* expression plasmid was transformed into *S. cerevisiae* and transformed yeast cells were tested for their ability to express *opd* using relative RT-PCR.

A *Flavobacterium opd* gene in plasmid pJK33, a pUC18 construct, was used. The *Flavobacterium opd* gene is identical to the *Pseudomonas putida opd* gene (Mulbry WW & Karns JS., (1989) J Bacteriol 171, 6740-6). A 1kb *opd* fragment was

PCR-amplified using a proofreading thermostable polymerase (**Fig. 1**). The 5' primer was designed to incorporate a yeast ribosome binding site to ensure optimal translation initiation (Looman AC & Kuivenhoven JA., (1983) Nuc Acids Res 21, 4268-71). The 5' and 3' primers were also designed to incorporate the restriction endonuclease sites *Bam*HI and *Hind*III, respectively. The *opd* gene was directionally cloned into the corresponding sites of the *S. cerevisiae* expression vector pESC-URA (Table 1) using standard molecular biology techniques to create pOPD-ESC-URA. Diagnostic restriction endonuclease digestion (*Bam*HI and *Hind*III) and agarose gel electrophoresis confirmed a correct clone had been selected (**Fig. 2**). The sequence of the PCR-amplified *opd* gene was verified by deoxy dye terminator sequencing. The pOPD-ESC-URA plasmid contained the yeast 2 μ origin and the *URA3* auxotrophic marker gene for growth and selection in *S. cerevisiae*, the ColE1 origin and β -lactamase gene for growth and selection in *E. coli*, the GAL1 regulatable promoter for repressed (dextrose) or induced (galactose) expression in *S. cerevisiae*, and a transcription terminator (TCYC1) downstream of the *opd* gene (**Fig. 3**). A yeast expression plasmid containing a yeast codon optimized *opd* gene was also constructed. Codon optimization was performed by Bio S&T (Quebec, Canada). The sequence of the codon optimized *opd* gene is listed in the (**Fig. 4A**). The codon optimized *opd* gene was cloned into pESC-URA to create pYOPD-ESC-URA using the same cloning strategy as the wild-type *opd* gene.

S. cerevisiae was transformed (episomal expression) with the control (pESC-URA) and test plasmids (pOPD-ESC-URA) using the LiAc transformation procedure (Ito H et al., (1983) J Bacteriol 153, 163-8); yeast transformants were readily obtained. To verify that *opd* mRNA was expressed adequately, relative RT-PCR analysis was performed (**Fig. 5**). Transformants harboring control (pESC-URA) and test (pOPD-ESC-URA) plasmids were grown in synthetic dropout media (SD) under conditions that either repressed (dextrose medium) or induced (galactose medium) expression from the GAL1 promoter. Total RNA was prepared using Tri reagent (Ambion) according to the manufacturers' instructions and treated with DNaseI. Equal amounts of RNA (approximately 1 μ g) were reverse transcribed into cDNA using the retroscript kit (Ambion). PCR was performed initially with primers designed against the *S. cerevisiae* housekeeping gene actin (ACT1, 547 bp product) to

ensure equal amounts of cDNA were used for each sample; if required, the amount of cDNA template was then adjusted accordingly before *opd* analysis. PCR products were resolved and analyzed using agarose gel electrophoresis. PCR analysis was also performed with samples that lacked reverse transcriptase (RNA samples); no RT-PCR products were detected from these samples as expected. *Opd* RT-PCR analysis indicated that: (i) RT-PCR products were not detected from transformed yeast cells harboring the control plasmid (as expected); (ii) RT-PCR products were detected from yeast cells harboring pOPD-ESC-URA indicating the yeast cells were transformed successfully and were expressing the *opd* gene, and (iii) *opd* expression was higher in conditions that induced expression from the Gal promoter (presence of galactose).

The yeast *opd* expression plasmid, containing yeast transcriptional and translation signals, was constructed successfully. Transformed yeast cells harboring the yeast *opd* expression plasmid expressed *opd* mRNA.

Example 2: Effect of *opd* expression on *S. cerevisiae* growth.

Recombinant *S. cerevisiae* W3031A harboring control (pESC-URA) or test (pOPD-ESC-URA) plasmids were grown in SD media lacking uracil under repressed (2% dextrose) or induced (2% galactose) conditions at 37°C and monitored for growth spectrophotometrically.

Both control and test cultures grew slower in minimal media containing galactose compared to dextrose. *S. cerevisiae* harboring the *opd* plasmid exhibited a slight reduction in growth compared to the 'empty' control plasmid (**Fig. 6**). This may simply be due to protein over-expression which 'drained' the metabolic activity of the cell, and therefore, reduced the growth rate.

Opd expression is not toxic to *S. cerevisiae*; however, there was a slight inhibition in the growth rate of yeast cells harboring the *opd* plasmid under inducing conditions.

Example 3: Effect of paraoxon on *S. cerevisiae* growth.

S. cerevisiae was grown overnight in complex YPD broth (yeast extract, peptone, dextrose) or in SD media supplemented with uracil and 2% galactose

(SDgal) at 37°C to stationary phase. At time zero, the culture was divided equally and incubated in the absence or presence of 0.5, 1.0, 2.0, and 4.0 mM paraoxon. Growth was monitored spectrophotometrically at OD₆₀₀.

0.5 mM paraoxon did not significantly inhibit the growth of *S. cerevisiae* (**Fig. 7A**); however, paraoxon caused growth retardation at higher concentrations. Therefore, as expected, paraoxon inhibited yeast growth in a dose-dependent manner presumably due to the genotoxic action of OP.

To examine whether recombinant OPH⁺ cells were 'resistant' to the toxic actions of paraoxon, the growth of wild-type and recombinant OPH⁺ cells was monitored in the presence or absence of 1 mM paraoxon. The growth of wild-type and OPH⁺ cells were both inhibited to a similar extent by 1 mM paraoxon (**Fig. 7B**). This suggested that OPH⁺ cells were not more resistant to the toxic actions of paraoxon. Without being limited to any particular mechanism of action, this may be due to: (i) the paraoxon hydrolysis products being toxic to yeast, and/or (ii) inability of (some) yeast cells to hydrolyze paraoxon due to a heterogeneous OPH⁺ population, i.e. the OPH⁺ plasmid was unstable and not stably maintained in yeast (Section 1.4, Table 2).

Paraoxon inhibited *S. cerevisiae* growth in a dose-dependent manner. High concentrations of paraoxon (4.0 mM) resulted in a prolonged lag phase.

Example 4: Ability of yeast enzyme lysates to hydrolyze paraoxon.

S. cerevisiae W3031A, harboring pESC-URA (empty plasmid control) and pOPD-ESC-URA plasmids, was grown in SD media containing 2% galactose (pGAL1 inducing conditions). During the exponential phase of growth, yeast cells were harvested by centrifugation, and cell pellets were frozen. Enzyme lysates were prepared by incubating the cells with 0.5 ml Y-MER dialyzable lysis buffer (Pierce Biotechnology) for 20 min at room temperature (RT), followed by centrifugation at 24,000 x g for 15 min at 4°C. To measure cytosolic paraoxonase activity, 25 µl of the supernatant was mixed with 975 µl of reaction buffer (50 mM HEPES pH 7.5, 0.5 mM paraoxon, 2% methanol). For the triton extractable enzyme assay (membrane associated), the membrane pellet from the centrifugation step was resuspended in 100 µl of 1% triton X 100 in 50 mM HEPES pH 7.5, incubated for 20 min at RT, and

then centrifuged for 2 min at 15,000 rpm. The resulting supernatant was applied as for the cytosolic fraction. *P*-nitrophenol release was measured at 405 nm using a spectrophotometer for 5 min after the baseline stabilized. At least 3 replicates were measured per sample. Paraoxonase activity was calculated using the extraction
 5 coefficient of $1.7 \times 10^4 \text{ M}^{-1}\text{cm}^{-1}$ and presented as $\mu\text{moles paraoxon hydrolyzed/min/mg protein}$. The activities of yeast lysates were compared to lysates prepared from *E. coli* harboring an optimized bacterial *opd* expression plasmid.

Control enzyme lysates, prepared from yeast cells harboring the empty plasmid, were not able to hydrolyze paraoxon. In contrast, yeast cells harboring the
 10 *opd* expression plasmid, produced functional OPH protein that hydrolyzed paraoxon (Table 1). Most (75%) of the enzyme activity in *S. cerevisiae* was membrane associated (triton extractable) with the remainder in the cytosolic fraction. This distribution is comparable to the wild-type *Flavobacterium* species (Mulbry WW & Karns JS., (1989) J Bacteriol 171, 6740-6). No difference in paraoxonase activity was
 15 detected in lysates prepared from yeast cells harboring the wild-type *opd* gene or a yeast codon-optimized *opd* gene; this suggests that codon bias may not be a limiting determinant for efficient *opd* expression in yeast.

20 **Table 1.** Paraoxonase activity of enzyme lysates prepared from *S. cerevisiae* harboring pOPD-ESC-URA and *E. coli* harboring an optimized *opd* expression plasmid

Protein fraction	Specific activity ¹	
	<i>S. cerevisiae</i> ²	<i>E. coli</i> ³
Cytosolic	0.208	7.6
Triton extractable	0.644	1.1
% of triton extractable/total	75	13

¹ Specific activity represents $\mu\text{moles paraoxon hydrolyzed/min/mg total protein}$

² Average of 3 cultures after subtraction for background activity from control cultures

25 ³ Data from a single culture after subtraction for background activity from control cultures

Higher paraoxonase activity was evident in *E. coli* lysates harboring an optimized *opd* bacterial expression plasmid compared to yeast lysates. The higher activity may be attributed to a gene dosage effect. For example, the copy number of
 30 the *E. coli* plasmid (ColE1 origin of replication) is typically 300-500 plasmids per cell while the corresponding copy number of the yeast 2μ plasmid is approximately 30-50

plasmids per cell (Orr-Weaver TL & Szostak JW (1983) Mol Cell Biol 3, 747-9) or about 10-fold lower. In addition, the yeast plasmid was found to be unstable and not maintained consistently in the yeast population. Plating yeast cells harboring the yeast plasmids onto selective and non-selective media indicated that only 20-25% of the yeast cells maintained the plasmid (**Table 2**). Therefore, the specific activity of the yeast lysates may be underestimated compared to *E. coli*. The instability or low segregational stability of the yeast 2 μ plasmid has been reported previously (Murray AW & Szostak JW (1983) Cell 34, 961-70). This issue can be rectified by stably integrating the *opd* gene into the *S. cerevisiae* genome. Stable yeast cells with up to 100 copies of the integrated sequence can be generated by targeted homologous recombination (Parekh R et al., (1995) Protein Expr Purif 6, 537-45; Parekh RN et al., (1996) Biotechnol Prog 12, 16-21).

Table 2. Stability¹ of *S. cerevisiae* W3031A harboring pESC-URA and pOPD-ESC-URA

Plasmid	CFU/ml (non-selective) ²	CFU/ml (selective) ³	Cells maintaining the plasmid (%)
pESC-URA	6.57 x 10 ⁸	1.65 x 10 ⁸	25
pOPD-ESC-URA	3.37 x 10 ⁸	6.77 x 10 ⁷	20

¹Results are averages from 3 independent cultures

²Non-selective media, YPD

³Selective media, SD-URA

Recombinant yeast cells harboring the *opd* expression plasmid produced functional OPH protein capable of hydrolyzing paraoxon. Most of the enzyme activity was membrane-associated which is analogous to the wild-type *Flavobacterium* enzyme. Expression of *opd* from the yeast 2 μ plasmid most likely results in a heterogeneous OPH⁺ population due to plasmid instability.

Example 5: Ability of intact recombinant yeast to hydrolyze paraoxon.

Exponentially growing *S. cerevisiae* W3031A, harboring the pESC-URA (control) or pOPD-ESC-URA plasmids, was grown in SD media containing 2% galactose (pGAL1 inducing conditions). The yeast cells were harvested by centrifugation, and paraoxonase assays were performed using intact cells. As a

comparison, whole cell paraoxonase activity was also measured from *E. coli* cultures harboring a bacterial *opd* optimized expression plasmid.

Intact yeast cells harboring the *opd* expression plasmid were able to hydrolyze paraoxon (**Table 3**). Yeast cells exhibited 3- to 4-fold higher paraoxonase activity than intact *E. coli* cells. Yeast enzyme lysates and intact cells displayed different amounts of paraoxonase activity; intact cells exhibited only 2-3% of the total activity of the cell. Without being limited to any particular mechanism of action, a limitation of the ability of intact yeast cells to hydrolyze paraoxon may be the rate of entry of paraoxon into the cell (Mulchandani A et al., (1999) *Biotechnol Bioeng* 63, 216-23; Shimazu M et al., (2003) *Biotechnol Prog* 19, 1612-4). The barrier that limits the rate of entry into the cell may be either the cell wall or cell membrane.

Table 3. Whole cell paraoxonase activity of *S. cerevisiae* harboring pOPD-ESC-URA and *E. coli* harboring an optimized *opd* expression plasmid

Whole cell activity ¹	
<i>S. cerevisiae</i> ²	<i>E. coli</i> ³
0.231	0.062

¹ Whole cell activity represents $\mu\text{moles paraoxon hydrolyzed/min}/10^9 \text{ CFU}$

² Average of 3 cultures after subtraction for background activity from control cultures

³ Data from a single culture after subtraction for background activity from control culture

Intact recombinant yeast cells were capable of hydrolyzing paraoxon and functioning as a yeast biocatalyst. Intact yeast cells displayed lower paraoxon hydrolysis compared to enzyme lysates presumably because a rate limiting step is the rate of paraoxon diffusion into the cell.

Example 6: Ability of spheroplasts to hydrolyze paraoxon.

Exponentially growing *S. cerevisiae* W3031A harboring pOPD-ESC-URA was grown in SD media containing 2% galactose (pGAL1 inducing conditions). The yeast cells were harvested by centrifugation, divided equally, and were incubated in spheroplast buffer (1.2 M sorbitol, 50 mM EDTA, 50 mM potassium phosphate pH 7.5) in the presence or absence of 1 $\mu\text{l/ml}$ β -mercaptoethanol and 15 $\mu\text{l/ml}$ zymolyase (5 units/ μl , cell wall removal enzyme) at 37°C. After 20 min, spheroplast formation was confirmed by microscopic examination of lysed cells by the addition of 0.2%

SDS (1:1 mixing) and by the inability of spheroplasts to form a colony after 48 h growth on selective medium. The control cells and spheroplasts were washed (1,800 x g, 5 min) four times with 1M sorbitol, 50 mM HEPES pH 7.5 prior to assaying for paraoxon hydrolysis.

5 Paraoxon hydrolysis of spheroplasts, which lack a cell wall, was compared to intact yeast cells. There was no substantial difference in paraoxon hydrolysis between intact control cells and spheroplasts (**Table 4**). Thus, in some embodiments, removal of the cell wall does not increase the rate of paraoxon entry into the cell, and hence increase the paraoxon hydrolysis of the yeast biocatalyst. Therefore, a likely barrier
10 to paraoxon entry in one or more of these embodiments is the yeast cell membrane.

Table 4. Whole cell paraoxon hydrolysis of *S. cerevisiae* control and spheroplast cells harboring pOPD-ESC-URA

Whole cell <i>S. cerevisiae</i> activity ^{1,2}	
Intact control cells	Spheroplasts
0.041	0.038

¹ Whole cell activity represents $\mu\text{moles paraoxon hydrolyzed}/\text{min}/10^9 \text{ cells}$

² Number of cells determined microscopically using a haemocytometer

15

Removal of the cell wall did not improve whole cell paraoxon hydrolysis in some embodiments. This suggests that paraoxon cell entry may not be impeded by the cell wall.

20

Example 7: Ability of permeabilized yeast to hydrolyze paraoxon.

S. cerevisiae W3031A harboring pOPD-ESC-URA plasmids, was grown in SD media containing 2% galactose (pGAL1 inducing conditions). At OD₆₀₀ 0.5, the yeast cells were harvested by centrifugation, divided equally, and incubated in TE
25 buffer (1 mM EDTA, 10 mM Tris-HCl pH 7.5) in the presence or absence of dimethylsulphoxide containing 0.1% digitonin at 30°C (Becker JM et al., (1988) Biochim Biophys Acta 968, 408-17). After 15 min shaking, the presence of permeabilized cells was assessed by the addition of 0.4% trypan blue (1:1 mixing). Microscopic examination indicated that 99% of the digitonin-treated cells appeared
30 blue (per field of vision) while control cells remained opaque. The appearance of 'blue' yeast cells is indicative of a damaged, or permeabilized membrane. Digitonin-

treated cells also exhibited a 10^3 -fold lower viable cell count after 48h incubation onto selective medium as expected. The control and permeabilized cells were washed (2,000 x g, 10 min) four times with TE buffer prior to assaying for paraoxonase activity.

5 Treatment of the cells with the permeabilization agent digitonin increased paraoxon hydrolysis 3 to 4-fold compared to control cells (**Table 5**). This suggests that disrupting the yeast membrane increases the rate of paraoxon entry into the cell and hence the yeast biocatalytic activity. This is in agreement with research using bacterial biocatalysts which have shown that the bacterial cell envelope acts as a
10 permeability barrier to the substrate. For example, OPH expressed on the bacterial cell surface hydrolyzes OP compounds more effectively than whole cell biocatalysts where OPH resides within the cytoplasm. Permeabilizing the outer membrane using solvents can overcome these issues and increase the rate of passive diffusion and hydrolysis, although practicing these methods may require care to be taken to avoid
15 cell death.

Table 5. Whole cell paraoxon hydrolysis of *S. cerevisiae* control and permeabilized cells harboring pOPD-ESC-URA

Whole cell <i>S. cerevisiae</i> activity ^{1,2}	
Control cells	Permeabilized cells
0.0064	0.023

¹ Whole cell activity represents μ moles paraoxon hydrolyzed/min/ 10^9 cells

20 ² Number of cells determined microscopically using a haemocytometer

Permeabilization of the yeast membrane increased the efficiency of the yeast biocatalyst presumably by disrupting the membrane and thereby increasing the rate of paraoxon entry into the cell. The results suggest the yeast membrane is the primary
25 barrier to paraoxon entry.

Example 8: Effect of membrane permeating agents such as ethanol on paraoxon hydrolysis.

Yeast cells harboring the pOPD-ESC-URA plasmid were grown in SD media
30 containing 2% galactose (pGAL1 inducing conditions) and either 2%, 4%, 6% or 8% ethanol (final concentration). Growth was monitored spectrophotometrically at OD₆₀₀

and cell viability was examined by trypan blue staining. The ability of yeast cells pretreated with sub-lethal concentrations of ethanol were examined for whole cell paraoxon hydrolysis.

Incubation with 2 or 4% ethanol resulted in a decrease in *S. cerevisiae* growth rate; incubation with higher ethanol concentrations (6-8%) severely inhibited growth (Fig. 8); however, there was no difference in the viability between control and 4% ethanol-treated cells after 3.75 h treatment. Therefore, yeast cells harboring pOPD-ESC-URA were pretreated with 2 or 4% ethanol for 4.5h prior to performing paraoxonase assays. Pretreatment with sub-lethal concentrations of ethanol increased whole cell paraoxon hydrolysis (Table 6). Pretreatment with 2% ethanol prior to the assay increased whole cell activity 1.29-fold while pretreatment with 4% ethanol increased activity 1.46-fold compared to control cells.

Table 6. Whole cell paraoxon hydrolysis of *S. cerevisiae* harboring pOPD-ESC-URA pretreated with sub lethal concentrations of ethanol

Treatment	Whole cell activity ¹	Fold-increase ²
Control ³	0.28	-
2% Ethanol ³	0.36	1.29
4% Ethanol ³	0.41	1.46

¹ Whole cell activity represents $\mu\text{moles paraoxon hydrolyzed/min}/10^9$ cells

² Fold-increase compared to control cultures

³ No difference in viability (trypan blue staining) was observed for the different treatments

Pretreatment with sub-lethal concentrations of ethanol increased whole cell paraoxon hydrolysis most likely by increasing the membrane permeability to paraoxon. Ethanol pretreatment can increase yeast biocatalytic activity.

Example 9: Sensitivity of yeast membrane mutants to paraoxon.

Yeast mutants, with specific mutations in ergosterol biosynthesis, may be hypersensitive to paraoxon due to increased paraoxon diffusion through the altered yeast membranes. Therefore, growth curves in the presence or absence of a low concentration of paraoxon were performed to examine yeast membrane mutant strains for increased sensitivity to paraoxon. *S. cerevisiae* wild-type BY4741, and the

membrane mutant strains *erg3*, *erg4* and *erg6* were grown overnight in complex YPD broth (plus 200µg/ml G418 for the mutant strains) at 37°C to stationary phase. At time zero, the cultures were divided equally and incubated in the absence or presence of 0.5 mM paraoxon. Cultures were monitored for growth spectrophotometrically at
5 OD₆₀₀.

There was no difference in the growth rates between the wild-type and *erg3* or *erg4* strains in the presence or absence of 0.5 mM paraoxon, (Figs. 9A & B). This indicated that mutations in ERG3 and ERG4, did not confer increased sensitivity to paraoxon. In contrast, 0.5 mM paraoxon resulted in a significant decrease in the
10 growth rate of *erg6*, compared to the wild-type strain (Fig. 9C).

To examine the degree of sensitivity of *erg6* to paraoxon, additional growth curves were performed with lower (0.25 mM and 0.125 mM) paraoxon concentrations. The growth rate of *erg6* was inhibited by 0.125 mM paraoxon, while this concentration had no effect on the wild-type strain (Figs. 10A & B). Therefore,
15 the results indicate that *erg6* is hypersensitive to paraoxon and may be useful for incorporation into a yeast biocatalyst; however, a potential drawback of using the *erg6* mutant is that growth rates in YPD medium are impaired compared to the wild-type strain (Welihinda AA et al., (1994) Biochim Biophys Acta 1193, 107-17).

The specific membrane mutant *erg6* is hypersensitive to paraoxon, presumably
20 due to the increased permeability of the defective membrane to paraoxon. The use of yeast membrane mutants such as *erg6* may increase the efficiency of the biocatalyst.

Example 10: Microarray analysis of wild-type and recombinant OPH⁺ yeast gene expression.

25 Global transcription profiling (microarray analysis) was performed on *S. cerevisiae* in the presence or absence of paraoxon, and on recombinant OPH⁺ yeast in the presence or absence of paraoxon. The comparison between wild-type cells incubated with paraoxon, and recombinant cells expressing OPH incubated with paraoxon, identified yeast genes, which were induced by the hydrolysis of paraoxon.

30 *S. cerevisiae* W3031A was grown at 37°C in SDgal (induced expression) in the presence or absence of 3 mM paraoxon for 60 min; these samples were used to identify yeast genes which were upregulated in the presence of paraoxon. Cultures

were also prepared from the recombinant OPH⁺ strain in the presence or absence of 3 mM paraoxon for 60 min. These samples permitted the identification of induced genes, which were specific to paraoxon hydrolysis. RNA was prepared from triplicate cultures using TRI reagent (Ambion) according to the manufacturers' instructions.

5 RNA preparations were treated with DNaseI and then further purified by passing the RNA through RNeasy columns (Qiagen).

Biotin-labeled, fragmented cRNA targets was prepared from 10µg of total RNA using standard protocols established for the Affymetrix GeneChip System (Santa Clara, CA). Targets were hybridized to the Affymetrix GeneChip® Yeast

10 Genome S98 Array which contains the entire *S. cerevisiae* genome (approximately 6,200 ORFs) on a single array. Hybridizations were performed in triplicate using three RNA preparations from three independent cultures. Post-hybridization washing, staining and scanning were performed using standard conditions developed by Affymetrix. Microarray hybridization data (CEL files) were normalized using the

15 Bioconductor implementation of GCRMA (Gentleman RC et al., (2004) Genome Biol 5, R80), and normalized hybridization data were imported into analysis program dChip for pairwise comparison of treatments. Paraoxon induced genes were defined by the following criteria: increase in expression greater than 4-fold and statistical difference (unpaired *t*-test, $p < 0.01$) for wild-type treated versus untreated and

20 recombinant treated versus untreated. Candidate genes associated with paraoxon hydrolysis were defined by the following criteria: increase in expression greater than 2-fold and statistical difference (unpaired *t*-test, $p < 0.01$) for recombinant paraoxon treated versus recombinant untreated excluding paraoxon-induced genes. Hierarchical clustering was performed on each set of candidate genes with dChip

25 using standardized expression values (z-normalization) with a distance metric of 1-correlation and linkage calculated by the centroid method.

Overall, the number of genes induced by paraoxon and the changes in expression were large. For example, pairwise comparisons for fold change ($p < 0.01$) using the *t*-test for comparing paraoxon treated to untreated control cells, identified

30 approximately 1,900 genes that were differentially expressed. The false discovery rate (FDR) for differential expression was low (0.3%) indicating that only about 6 of the 1,900 genes were estimated to be wrong. 65 genes were identified to be

differentially expressed due to paraoxon exposure and were selected by: (i) 4-fold differential expression or greater; (ii) statistically significant based on the *t*-test with a *p* value <0.01; (iii) increased expression only (not repressed) and (iv) induced by paraoxon from both treatment sets (wild-type and recombinant yeast). A selected list of 7 paraoxon-inducible genes, based upon fold-induction, is depicted in **Table 7**. The level of differential expression ranged from 18 up to 1,700-fold induction (for YGR035C) and thus represented large increases in expression levels. Four out of the 7 paraoxon-inducible genes have unknown functions; however, a common theme for gene function assignment is drug resistance which is not unexpected.

10

Table 7. Selected list of paraoxon-inducible genes

Accession	Name/Alias	Fold-induction	P-value	Description
YGR035C	None	1789.2	0.000	Function unknown; activated by Yrm1p and Yrr1p along with genes involved in MDR.
YHR139C	SPS100	719.1	0.000	Protein required for spore all maturation; expressed during sporulation; may be a component of the wall.
YOR186W	None	269.1	0.000	Hypothetical protein
YGR213C	RTA1	152.2	0.001	Protein involved in 7-aminocholesterol resistance.
YLR346C	None	69.6	0.003	Unknown function; regulated by PDR1 (pleiotrophic drug resistance 1).
YIR017C	MET28	27.7	0.004	Participates in sulfur metabolism; stress response
YLL056C	None	18.5	0.000	Unknown; activated by Yrm1p and Yrr1p? MDR? Similar to YGR035C.

The number of genes and the level of differentially regulated genes associated with paraoxon hydrolysis in this specific example were not as extensive as the paraoxon-inducible genes. The reason why fewer genes were identified may be due to: (i) the 60 min paraoxon incubation time was insufficient to hydrolyze enough paraoxon to change the transcriptional profile, or (ii) the OPH⁺ plasmid was unstable and therefore a large percentage of the population were not capable of producing paraoxon-hydrolyzed products. Nevertheless, 33 differentially expressed genes were

15

associated with paraoxon hydrolysis. Genes were chosen on the following criteria: (i) 2-fold differential expression or greater; (ii) statistically significant based on the *t*-test with a *p* value <0.01; (iii) increased expression only (not repressed), and (iv) exclusion of genes that were induced only by paraoxon. A selected list of 4 genes associated with paraoxon hydrolysis is depicted in **Table 8**. Differential expression ranged from 4- to 7-fold induction. Two of the 4 gene products have unknown functions.

Table 8. Selected list of genes associated with paraoxon hydrolysis

Accession	Name/Alias	Fold-induction	P-value	Description
YGL205W	POX1/FOX1	6.96	0.001	Fatty-acyl coenzyme A oxidase, involved in the fatty acid beta-oxidation pathway; localized to the peroxisomal matrix.
YJL219W	HXT9	3.94	0.004	Putative hexose transporter.
YGR287C	None	3.86	0.01	Unknown.
YHL012W	None	3.84	0.007	Unknown.

Microarray analysis identified paraoxon-inducible yeast genes and yeast genes associated with paraoxon hydrolysis. Some of these genes were massively induced and are ideal candidates for the promoter-reporter genes fusions.

Example 11: Prioritization of paraoxon-inducible genes.

The genes isolated by the microarray analysis were verified individually for differential expression by relative RT-PCR and quantitative real-time RT-PCR. The paraoxon-inducible genes are listed in Table 7. Prioritized genes, based on fold-induction, were analyzed to investigate whether they were induced by low concentrations of paraoxon in a dose dependent manner (0.05 to 1.0 mM). Prioritized genes, which were sensitively induced by paraoxon, were examined after various paraoxon exposure times (7.5, 15, and 30 min). Priority was given to genes that displayed characteristics that were preferential for the construction of the yeast biosensor. These included genes which displayed: (i) the greatest fold induction; (ii) sensitivity to lower concentrations of paraoxon than that used for the microarray analysis (3 mM), and (iii) quick induction response times.

Relative RT-PCR analysis was used to verify whether the genes identified by the microarray analysis, were differentially expressed in response to paraoxon. Primers designed against the housekeeping gene actin, were used as an internal loading control to verify that similar amounts of cDNA were used for each PCR reaction. Increased expression of YGR035C, YLR346C, SPS100, YOR186W, RTA1, MET28, and YLL056C were detected for wild-type and recombinant OPH⁺ yeast cells grown in the presence of 3 mM paraoxon for 60 min (lanes CP and TP, **Fig. 11**). Therefore, relative RT-PCR was able to individually verify that the genes identified by the microarray analysis, were differentially expressed in response to paraoxon. Since YLR346C and YGR035C were shown to be significantly induced by both microarray analysis and relative RT-PCR, they were prioritized for further analysis.

Real-time RT-PCR was used to quantify changes in prioritized genes YGR035C and YLR346C in response to paraoxon. YGR035C was induced 35-fold to 190-fold in paraoxon-treated cells compared to untreated controls. YLR346C was induced 17-fold to 31-fold for the equivalent experimental samples. Therefore, real-time RT-PCR confirmed that YGR035C and YLR346C were significantly induced.

To examine if the paraoxon genes were sensitively induced at paraoxon concentrations lower than that used for the microarray analysis (3 mM paraoxon), *S. cerevisiae* W3031A harboring pESC-URA was exposed to 0.05, 0.1, 0.25, 0.5 and 1.0 mM paraoxon for 60 min. Relative and real-time RT-PCR was performed to examine changes in gene expression. Relative RT-PCR indicated that there were no obvious changes in gene expression for YOR186W, SPS100 and RTA1 at the lower paraoxon concentrations tested (**Fig. 12**). In contrast, YGR035C was induced 18- and 31-fold by 0.5 and 1.0 mM paraoxon, respectively. Similarly, YLR346C was induced 8- and 10-fold by 0.5 and 1.0 mM paraoxon, respectively (**Fig. 13**). Therefore, YGR035C and YLR346C responded to a range of paraoxon concentrations in a sensitive manner compared to YOR186W, SPS100, and RTA1 and were prioritized for further analysis.

Microarray analysis identified genes which were induced by paraoxon after 60 min exposure. Since genes which are quickly induced by paraoxon will be preferable, YGR035C and YLR346C were examined for their ability to be induced in response to short paraoxon incubations. *S. cerevisiae* harboring pESC-URA was exposed to 2.5 mM paraoxon for 7.5, 15, 30, and 60 min and relative and real-time RT-PCR was

used to examine changes in gene expression. Both YGR035C and YLR346C were significantly and maximally (98- and 32-fold, respectively) induced after 7.5 min (**Fig. 14**). Continued exposure (up to 60 min) resulted in a decrease in fold-induction compared to the initial 7.5 min value.

- 5 Real-time RT-PCR was used to quantify changes in gene expression and confirmed the differential regulation of the paraoxon-inducible gene candidates identified by the microarray analysis. YGR035C and YLR346C were prioritized for use in Examples 13-14 since they: (i) are significantly induced up to 190 and 32-fold, respectively; (ii) are sensitive to a range of paraoxon concentrations, and (iii) are
10 induced after 7.5 min exposure to paraoxon.

Example 12: Prioritization of genes associated with paraoxon hydrolysis.

The genes identified by the microarray analysis (**Table 8**) were verified individually for differential expression by real-time RT-PCR.

- 15 Real-time RT-PCR was used to examine YHL012W, HXT9, POX1, and YGR287C expression from wild-type yeast cells in the absence or presence of paraoxon (C and CP, respectively), and recombinant OPH⁺ yeast in the absence or presence of paraoxon (T and TP respectively). There was no difference in YHL012 expression in the presence or absence of paraoxon, or between the wild-type and
20 recombinant yeast (**Table 9**). HXT9 expression was induced approximately 3-fold by paraoxon; however paraoxon induced HXT9 expression in both wild-type and recombinant OPH⁺ yeast cells indicating that HXT9 induction was not associated with *opd* expression and hence paraoxon hydrolysis. This indicates that real-time PCR was not able to verify the results of the microarray for the candidate genes YHL012 and
25 HXT9. In contrast, an increase in POX1 expression (2.4-fold) was detected only in recombinant OPH⁺ yeast in the presence of paraoxon indicating that POX1 expression was associated with paraoxon hydrolysis. Similarly, YGR287C expression was increased 9-fold in recombinant OPH⁺ yeast cells in the presence of paraoxon; however, paraoxon also induced YGR287C in wild-type cells, albeit to a much lesser
30 extent (2-fold).

Table 9. Real-time RT-PCR analysis of the candidate genes

associated with paraoxon hydrolysis

Accession/name	C ^a	Fold-induction		
		CP ^b	T ^c	TP ^d
YHL012W	1.0	0.8	1.0	1.0
HXT9	1.0	2.8	1.0	2.7
POX1	1.0	0.9	1.0	2.4
YGR287C	1.0	1.9	1.0	9.1

^a *S. cerevisiae* W3031A harboring pESC-URA (empty plasmid)

^b *S. cerevisiae* W3031A harboring pESC-URA (empty plasmid) incubated with 3 mM paraoxon

5 ^c *S. cerevisiae* W3031A harboring pOPD-ESC-URA (expressing *opd*)

^d *S. cerevisiae* W3031A harboring pOPD-ESC-URA (expressing *opd*) incubated with 3 mM paraoxon

Real-time RT-PCR confirmed that POX1 and YGR287C were preferentially
 10 expressed in recombinant OPH⁺ yeast in the presence of paraoxon, suggesting induction was associated with paraoxon hydrolysis. Therefore, POX1 and YGR287C were prioritized for use in Examples 13-14.

Example 13: A yeast YeGFP biosensor that detects paraoxon.

15 A plasmid containing a yeast codon optimized enhanced GFP (YeGFP) gene was constructed. The promoter regions (-500 and -1000 bp upstream fragments) of the 2 prioritized paraoxon-inducible genes identified in Example 11 (YGR035C and YLR346C) were cloned, fused to YeGFP and transformed into wild-type *S. cerevisiae*. The sequence of YGR035C-FI-YeGFP is shown (**Fig. 15A**; bold, promoter sequence; underline, YeGFP gene sequence). The sequence of pYLR346C-FI-YeGFP is shown (**Fig. 15B**; bold, promoter sequence; underline, YeGFP gene sequence). The functionality of the yeast biosensor was examined by measuring YeGFP fluorescence after different exposure times to paraoxon, and in the presence of different concentrations of paraoxon.

25 **Construction of a YeGFP promoterless yeast vector.** YeGFP is an *Aequorea victoria* GFP variant that has 2 amino acid changes which increases fluorescence intensity 75 times more than the wild-type GFP. In addition YeGFP is

codon optimized for expression in the yeast *Candida albicans*, and is also highly fluorescent in *S. cerevisiae* (Cormack BP et al., (1997) Microbiology 143, 303-11). A strain of *C. albicans* containing YeGFP was used. The 700 bp YeGFP gene was PCR-amplified using a proofreading polymerase and *C. albicans* YeGFP genomic DNA as template. The PCR primers were designed to contain *Bam*HI and *Spe*I endonuclease sites for cloning into the respective sites of pESC-HIS. The resulting 'promoterless' pYeGFP-HIS plasmid, contained a multiple cloning site (MCS, *Bam*HI, *Sma*I, *Sal*I, *Xho*I, and *Sac*I) for cloning the paraoxon-inducible promoters. Cloning and propagation was performed in *E. coli* ER2738. The identity of YeGFP was verified by DNA sequencing.

Construction of paraoxon-inducible promoter-YeGFP fusion reporter plasmids. The promoter sequences were initially mapped using the *Saccharomyces* promoter database (SCPD) (maintained by Cold Spring Harbor Laboratories, Cold Spring Harbor, NY). The SCPD has extensive information on yeast genes with previously mapped regulatory regions, has annotated putative regulatory sites of all yeast genes, and has extensive tools for the retrieval of promoter sequences and known regulatory elements for the gene of interest. Although the promoters of the 2 prioritized paraoxon-inducible genes (YGR035C and YLR346C) had not been previously mapped in the literature, analysis of the 5' upstream promoter regions using the SCPD, identified putative promoter regulatory sites involved in drug and stress resistance as expected. To encompass the YGR035C and YLR346C promoters, 2 putative promoter fragments for each gene containing approximately -1000 and -500 bp upstream sequence (relative to ATG) were cloned in front of YeGFP. The putative promoter regions were PCR-cloned using *S. cerevisiae* W3031A genomic DNA as template and a proofreading thermostable DNA polymerase. The 5' and 3' primers contained *Sal*I and *Bam*HI sites, respectively, for directional cloning into the same sites of pYeGFP-HIS to generate promoter-reporter gene fusions. The resulting plasmids were named F1 and F2 for the -1000, and -500 promoter fragments, respectively (Table 11).

Paraoxon-inducible promoter-YeGFP biosensor assays. To test whether the promoter regions conferred sensitivity to paraoxon, YeGFP fluorescence assays were performed. *S. cerevisiae* BY4741 was transformed with the promoter-reporter

constructs and the empty 'promoterless' control vector. *S. cerevisiae* BY4741 was used in preference to *S. cerevisiae* W3031A since W3031A exhibited higher autofluorescence than BY4741. Cells were grown in SDgal/suc (3% galactose, 1% sucrose) lacking histidine in the presence or absence of paraoxon for 15, 30, 60, and 120 min at 37°C. Cells were harvested by centrifugation, washed in PBS, resuspended in 10 mM Tris-HCl pH 8.5, and duplicate samples were measured for YeGFP fluorescence (excitation and emission max of 485 and 520 nm) using the FLUOstar OPTIMA (BMG). The samples were resuspended in alkaline buffer since GFP is pH sensitive. GFP is stable at pH 7 to 11.5, but may lose activity at other pHs (e.g., 50% lower at pH 6). Consequently, media and pH formulations, in some embodiments, may be optimized to maintain the pH of yeast cultures at or near a neutral pH. All results were normalized to the number of cells present (OD₆₀₀), to the 'promoterless' control vector (YeGFP-HIS) and are presented as fold-induction compared to cells lacking paraoxon. Yeast cells incubated in the presence of paraoxon exhibited increased YeGFP fluorescence compared to cells lacking paraoxon (Fig. 16). Yeast cells harboring pYLR346C and pYGR035C-YeGFP were induced 5 and 3-fold, respectively, after 2 h incubation with 3 mM paraoxon. Incubation with paraoxon for longer than 2 h (4, 6, 8, and 24 h) did not increase the fold-induction (data not shown). A time course analysis indicated that YeGFP fluorescence was quickly induced by paraoxon. For example, yeast strains harboring pYLR346 were induced 2-fold after only 15 min exposure to paraoxon.

To determine the sensitivity of the assay and to investigate whether the recombinant yeast responded to different paraoxon concentrations, a dose response curve was performed. *S. cerevisiae* harboring pYLR346C-F1-YeGFP was incubated with 0.1, 0.25, 0.5, 1.0, and 3 mM paraoxon for 2 h prior to assaying for YeGFP fluorescence. The construct harboring the promoter fragment YLR346C-F1 was chosen for this experiment since it was most responsive to 3 mM paraoxon (Fig. 16, 5-fold). As the concentration of paraoxon increased, the level of YeGFP induction increased (Fig. 17). In addition, the level of fluorescence increased, albeit modestly (1.3-fold), at the lowest concentration tested (0.1 mM paraoxon). Therefore, the results indicated that the yeast biosensor exhibited a dose response to paraoxon, and was responsive to 0.1 mM paraoxon.

YeGFP fluorescence was induced up to 5-fold in the presence of paraoxon. The level of YeGFP induction, however, was lower than the fold-change in gene expression observed under the same conditions (30-fold for YLR346C). Without being limited to any particular mechanism of action, this may be attributed to a sub-optimal promoter fragment driving YeGFP expression. Only 2 promoter fragments (approximately -500, and -1000 relative to the ATG) for each gene were tested. In some embodiments, additional promoter characterization may include 5' promoter deletion analysis to further identify the promoter fragment necessary to confer paraoxon inducibility. Additional promoter characterization may also include identification of sequence 3' of the ATG start site that may also contain regulatory transcriptional motifs.

In addition, the difference between YeGFP fluorescence and YeGFP expression may be reduced by providing additional transcription factor(s) required for inducing expression from the promoters located on multicopy plasmids. The YLR346C promoter is maintained at approximately 20-50 copies per cell on the multicopy plasmid while there is only a single copy of the chromosomal endogenous promoter. Consequently, the endogenous transcription factors required for paraoxon induction may be saturated by the presence of multiple transcription factor binding sites. Providing additional transcription factor(s) may include reducing the number of plasmid copies or coexpressing the required transcription factors (if known) may overcome this limitation. Background autofluorescence of yeast may lead to a reduction in the differential level of induced expression under some circumstances. In such cases, using yeast strains with lower background fluorescence, for example, *S. cerevisiae* BY4741 may offset or overcome autofluorescence. For example, *S. cerevisiae* W3031A displayed higher background autofluorescence than BY4741. Consequently, BY4741 was used as a host propagating strain for biosensor fluorescence assays.

Yeast cells harboring paraoxon-inducible promoter-YeGFP fusions displayed up to 5-fold increases in fluorescence levels compared to control cells when incubated in the presence of paraoxon. Increased YeGFP levels were detected after 15 min exposure to paraoxon. The YeGFP biosensor was sensitive to as low as 0.1 mM paraoxon and exhibited dose-dependent characteristics by increasing YeGFP

fluorescence as the paraoxon concentration increased. The results demonstrate the ability of yeast cells to function as a biosensor and detect the presence of paraoxon.

Example 14: A yeast YDsRed biosensor that detects paraoxon hydrolysis.

5 A plasmid containing a yeast codon optimized DsRed (YDsRed) gene was constructed. The promoter regions (-500 and -1000 bp upstream fragments) of the 2 prioritized paraoxon-inducible genes identified in Examples 10-12 (POX1 and YGR287C) were cloned, fused to YDsRed and transformed into wild-type and recombinant OPH⁺ *S. cerevisiae*. The sequence of YGR287C-FI-YDsRed is shown
10 (Fig. 18A; bold, promoter sequence; underline, YDsRed gene sequence). The sequence of pPOX1-FI-YDsRed is shown (Fig. 18B; bold, promoter sequence; underline, YDsRed gene sequence). The ability of the yeast biosensor to increase YDsRed fluorescence was compared in wild-type (control) and recombinant yeast cultures. YDsRed fluorescence was measured after different exposure times to
15 paraoxon, and in the presence of different concentrations of paraoxon.

Construction of a YDsRed promoterless yeast vector. DsRed-express (Clontech) is a variant of the coral reef *Discoma* species red fluorescent protein that has been modified to improve solubility of the protein and codon-optimized for high expression in eukaryotic cells for enhanced sensitivity. This results in high
20 fluorescence intensity, which is comparable to EGFP. Nevertheless, DsRed express contains a number of codons that are rarely used in *S. cerevisiae*. Therefore, DsRed was codon optimized for expression in yeast (performed by Bio S & T) (Fig. 4B). The yeast codon optimized DsRed, YDsRed, was also designed to contain a preferred yeast ribosome binding site and *Bam*HI and *Not*I restriction endonuclease sites for
25 cloning into the corresponding sites of pESC-LEU (Stratagene). The resulting pYDsRed-LEU promoterless vector contained an adequate MCS for cloning the POX1 and YGR287C promoters.

Construction of promoter-YDsRed fusion reporter plasmids. To encompass the POX1 and YGR287C promoters, 2 putative promoter fragments for
30 each gene containing approximately -1000 and -500 bp upstream sequence (relative to ATG) were cloned in front of YDsRed. The putative promoter regions were PCR-cloned using *S. cerevisiae* W3031A genomic DNA as template and a proofreading

thermostable DNA polymerase. The 5' and 3' primers contained *SalI* and *BamHI* sites, respectively, for directional cloning into the equivalent sites of pYDsRed-LEU to generate promoter-reporter gene fusions. The resulting plasmids were named F1 and F2 for the -1000, and -500 promoter fragments, respectively.

5 **Promoter-YDsRed biosensor assays.** To analyze whether the promoter regions were 'switched on' by paraoxon hydrolysis, YDsRed fluorescence assays were performed. *S. cerevisiae* BY4741 harboring pESC-URA (control strain lacking OPH) was transformed with the promoter-reporter constructs and the empty 'promoterless' control vector (pYDsRed-LEU). The recombinant OPH⁺ (test strain,
10 expressing OPH) was transformed with the analogous plasmids. Cells were grown in SDgal/suc lacking leucine in the presence or absence of 3 mM paraoxon for 4.5 h at 37°C. Cells were harvested by centrifugation, washed in PBS, resuspended in 10 mM Tris-HCl pH 8.5, and duplicate samples were measured for YDsRed fluorescence (excitation and emission at 554 nm and 590 nm, respectively). All results were
15 normalized to the number of cells present (OD₆₀₀), to the 'promoterless' control vector (YDsRed-LEU) and are presented as fold-induction compared to cells lacking paraoxon. Recombinant OPH⁺ cells, incubated in the presence of paraoxon, demonstrated induced YDsRed fluorescence compared to cells lacking paraoxon for all constructs analyzed (**Table 10**). Induction ranged from 2 to 8-fold, and is
20 comparable to the induction results obtained from the quantitative real-time RT-PCR. Importantly, the same constructs demonstrated little to no paraoxon inducibility in the control strain lacking OPH (pESC-URA empty vector). Therefore, YDsRed was not induced by paraoxon per se; induction required OPH indicating that YDsRed induction was strictly associated with paraoxon hydrolysis.

25

Table 10. YDsRed fold-induction from yeast cells grown in the presence of 3 mM paraoxon for 4.5 h*.

Control yeast (pESC-URA)		Recombinant OPH ⁺ yeast (pYOPD-URA)	
Promoter	Fold-induction ^a	Promoter	Fold-induction ^a
pYGR287C-F1	1.41	pYGR287C-F1	2.1
pYGR287C-F2	1.13	pYGR287C-F2	2.4
pPOX1-F1	0.84	pPOX1-F1	3.0
pPOX1-F2	0.74	pPOX1-F2	8.3

****S. cerevisiae* BY4741 control (pESC-URA) and recombinant OPH⁺ strains harboring the different promoter-YDsRed fusions**

^aSamples read in duplicate and normalized to OD₆₀₀ and the promoterless empty control vector (pYDsRed-LEU).

5

A time course analysis examining YDsRed induction was performed using the pPOX1-F2 YDsRed fusion construct. YDsRed fluorescence was measured 30, 60, 120, and 260 min after the addition of paraoxon for recombinant OPH⁺ cultures harboring the pPOX1-F2-YDsRed fusion (**Fig. 19**). A steady increase in YDsRed-
10 induction was observed as the exposure time to paraoxon increased. YDsRed fluorescence was induced 2.5-fold after 260 min exposure to paraoxon. To determine the sensitivity of the assay and to investigate whether the recombinant yeast responded to different paraoxon concentrations, a dose response curve was performed. *S. cerevisiae* OPH⁺ harboring pPOX1-F2-YDsRed was incubated with 0.1, 0.25, 0.5,
15 1.0, and 3 mM paraoxon for 255 min prior to assaying for YDsRed fluorescence. As the concentration of paraoxon increased, YDsRed-induction increased, albeit modestly (**Fig. 20**). Therefore, the results suggest that the yeast biosensor exhibited dose response characteristics to paraoxon hydrolysis.

The fluorescent protein DsRed was chosen for these experiments since: (i) it
20 has been successfully used as a reporter protein in yeast (Bevis BJ & Glick BS (2002) Nat Biotechnol 20, 83-7); (ii) it is a stable protein and (iii) it emits distinct spectral properties compared to YeGFP; however, the differential level of fluorescence between yeast cultures expressing YDsRed, and background autofluorescence levels (lacking YDsRed) was minimal. The low level of YDsRed expression may be
25 overcome following further experiments and optimization. To overcome this potential limitation and to increase the 'signal to noise ratio', the *Vibrio harveyi luxAB* reporter genes may be used to create a yeast biosensor that bioluminesces following OP hydrolysis. Bioluminescent yeast displaying similar light intensities to bacterial systems have been generated (Szittner R et al., (2003) Biochem Biophys Res
30 Commun 309, 66-70). Since yeast cells do not naturally bioluminesce, bioluminescent signals approaching 900,000-fold above background levels have been achieved (Gupta RK et al., (2003) Fems Yeast Res 4, 305-13). In addition, the use of a 'transient' luminescent signal (as opposed to a stable YDsRed fluorescent protein)

may enable the detection of increases and decreases in light emission. Consequently, a bioluminescent signal may be more suitable for monitoring the decontamination process.

Recombinant OPH⁺ yeast cells harboring promoters associated with paraoxon hydrolysis and fused to YDsRed, displayed between 2.5- to 8-fold YDsRed-induction levels in the presence of paraoxon. YDsRed induction was not observed in wild-type yeast cells (lacking OPH) suggesting that YDsRed induction was strictly associated with paraoxon hydrolysis. YDsRed induction increased with higher paraoxon concentrations indicating that the yeast biosensor responded to the amount of paraoxon hydrolyzed.

Table 11. Plasmids used and constructed in this study.

Plasmid name	Host species	Features
pJK33	<i>E. coli</i>	<i>Flavobacterium</i> OPD gene
pP1-SK	<i>E. coli</i>	<i>E. coli</i> optimized promoter (PI) in pBluescript SK-
pPI-SCOPD-SK	<i>E. coli</i>	PI driving OPD with yeast RBS
pPI-ECOPD-SK	<i>E. coli</i>	PI driving OPD with <i>E. coli</i> RBS
pOPD-OPT-SK	<i>E. coli</i>	Yeast codon optimized OPD in pSKII+
pESC-URA	<i>E. coli</i> / <i>S. cerevisiae</i>	Yeast expression vector/URA marker
pSCOPD-ESC-URA	<i>E. coli</i> / <i>S. cerevisiae</i>	GAL1 promoter driving OPD
pOPD-OPT-ESC-URA (pYOPD-ESC-URA)	<i>E. coli</i> / <i>S. cerevisiae</i>	GAL1 promoter driving yeast codon optimized OPD
pYDsRed-SKII+	<i>E. coli</i>	Yeast codon optimized DsRed express (YDsRed)
pESC-HIS	<i>E. coli</i> / <i>S. cerevisiae</i>	Yeast expression vector/HIS marker
pEGFP-NI	<i>E. coli</i> / <i>S. cerevisiae</i>	Mammalian vector containing 'enhanced' GFP
pEGFP-ESC-HIS	<i>E. coli</i> / <i>S. cerevisiae</i>	'promoterless' EGFP reporter plasmid
pGAL-EGFP-ESC-HIS	<i>E. coli</i> / <i>S. cerevisiae</i>	pGAL10 driving EGFP

pEGFP-YDsRed-ESC-HIS	<i>E. coli/S. cerevisiae</i>	Dual EGFP-YDsRed 'promoterless' reporter plasmid
pYeGFP-ESC-HIS	<i>E. coli/S. cerevisiae</i>	'promoterless' reporter plasmid containing the yeast codon optimized enhanced GFP (YeGFP)
pGAL-YeGFP-ESC-HIS	<i>E. coli/S. cerevisiae</i>	pGAL10 driving YeGFP
pESC-LEU	<i>E. coli/S. cerevisiae</i>	Yeast expression vector/LEU marker
pYDsRed-ESC-LEU	<i>E. coli/S. cerevisiae</i>	'promoterless' YDsRed reporter plasmid
pPOX1-F1-YDsRed-LEU	<i>E. coli/S. cerevisiae</i>	POX1 promoter (1002 bp upstream of ATG) driving YDsRed
pPOX1-F2-YDsRed-LEU	<i>E. coli/S. cerevisiae</i>	POX1 promoter (525 bp upstream of ATG) driving YDsRed
pYGR287C-F1-YDsRed-LEU	<i>E. coli/S. cerevisiae</i>	YGR287C promoter (993 bp upstream of ATG) driving YDsRed
pYGR287C-F2-YDsRed-LEU	<i>E. coli/S. cerevisiae</i>	YGR287C promoter (570 bp upstream of ATG) driving YDsRed
pGAL-YDsRed-ESC-LEU	<i>E. coli/S. cerevisiae</i>	pGAL1 driving YDsRed
pYGR035C-F1-YeGFP-ESC-HIS	<i>E. coli/S. cerevisiae</i>	YGR035C promoter (991 bp upstream of ATG) driving YeGFP
pYGR035C-F2-YeGFP-ESC-HIS	<i>E. coli/S. cerevisiae</i>	YGR035C promoter (455 bp upstream of ATG) driving YeGFP
pYLR346C-F1-YeGFP-ESC-HIS	<i>E. coli/S. cerevisiae</i>	YLR346C promoter (973 bp upstream of ATG) driving YeGFP
pYLR346C-F2-YeGFP-ESC-HIS	<i>E. coli/S. cerevisiae</i>	YLR346C promoter (476 bp upstream of ATG) driving YeGFP

Table 12. Strains used in this study.

Species/strain	Genotype	Source	Features
<i>E. coli</i> ER2738	F ⁺ proA ⁺ B ⁺ lacI ^Δ (lacZ)M15zzf.: Tn10(Tet ^R)/fhuA2 glnVΔ(lac-proAB)thi-1Δ(hsdS- mcrB)5	New England Biolabs	General lab cloning strain
<i>S. cerevisiae</i> W3031A	MATa ade2-1 ura3-1 his3-11 trp1-1 leu2-3 leu2-112 can1-100	Guild stock collection	Wild-type strain
<i>S. cerevisiae</i> BY4741	MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0	Guild stock collection	Wild-type strain
<i>S. cerevisiae</i> erg3	MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 ΔERG3	ATCC4002667	erg3 mutant strain
<i>S. cerevisiae</i> erg4	MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 ΔERG4	ATCC4004380	erg4 mutant strain
<i>S. cerevisiae</i> erg6	MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 ΔERG6	ATCC4000568	erg6 mutant strain

Table 13. Real-time PCR primers used in this study

Gene	Primers (forward and reverse)	SEQ ID NO	PCR product size (bp)
YGR035C	5'- GCGTGCCATAGTTTCTTCC	7	169
	5'- TCGTCCCTGAGACTTACTC	8	
SPS100	5'- AGTACCGTGGCATCATGGAC	9	128
	5'- GCAGAAATTGCACCTTGTGG	10	
YOR186W	5'- TTAAAGTCCGCCATACGAGC	11	139
	5'- CTGCCTACATCGCCAATCAC	12	
RTA1	5'- AATGGCTACTCTGCTGTTTCG	13	87
	5'- CTGCCTACATCGCCAATCAC	14	
YLR346C	5'- TGTCCCATCGGGTTAGTTTC	15	161
	5'- TGGGCAGCCTTGAGTAAATC	16	
MET28	5'- AAGCAGGAAGGGTATGAACG	17	100
	5'- CAGCAGCAATGATAGCAAGC	18	
YLL056C	5'- CAGCAGCAATGATAGCAAGC	19	189
	5'- CGGTCAATTTTCGCAGCACTG	20	
POX1	5'- AAGCTGCTCTGGTTACCGTG	21	134
	5'- ATACCCATGTCCTCCGCAAG	22	
HXT9	5'- AAGTTGTGGCCTCAAGGAAG	23	183
	5'- TGTTGCGATTGCCATTCCTC	24	
YGR287C	5'- ACTTGGCAATCCAGTGATCC	25	140
	5'- TCGGAGGCATGTTGCATTTC	26	
YHL012W	5'- TTGCCTTCTTTCCGAACAGT	27	173
	5'- GCCCAAGTCGATTGAAGGTA	28	
ACT1	5'- TTCCAGCCTTCTACGTTTCC	29	100
	5'- ACGTGAGTAACACCATCACC	30	

Table 14. PCR primers used in promoter fragment cloning procedures

Gene	Primers (2 forward and 1 reverse)	SEQ ID NO	PCR product size (bp)
YGR035C	5'- TTAAGTCGACAGAGTTTACTTGCACTACC	31	991
	5'- TTAAGTCGACGGAGATAATACCCTCTG	32	455
	5'- AATTGGATCCTACGTATTGTTTCTGTAGAG	33	
YLR346C	5'- AATTGTCGACTTTCTTCCTTTTCTACTATC	34	973
	5'- TTAAGTCGACAACCATCCTTAGCTTCC	35	476
	5'- TTATGGATCCTATTAAAGGTGATAAATAATCC	36	
POX1	5'- AATTGTCGACTTTCCTCAACCACCTCC	37	1002
	5'- TATAGTCGACTAGATTCCTTCAGTTCCAC	38	525
	5'- TTAAGGATCCATCGCAATACTAATTTATTATAT	38	
HXT9	5'- TTAAGTCGACACTTGGGTTCTGTTTCTGG	40	1000
	5'- ATTAGTCGACATACGGAGCGTAAACAACC	41	583
	5'- ATATGGATCCGATATTGGGTAAGATACGAA	42	
YLR287C	5'- TTAAGTCGACGGCTGTATGTTTATGATTGC	43	993
	5'- TTAAGTCGACGCTCTTAACTGCGTTTACC	44	570
	5'- TTAAGGATCCGATAGTAAATATTACGTTGA	45	
YHL012W	5'- TATTGTCGACGCCTCTTCTTTTCATTTTAGC	46	1000
	5'- ATTAGTCGACATTAGATGCTTTTCGAGATGC	47	523
	5'- TAATGGATCCTGATCTTGTATATACTATGTAG	48	

Bold indicates the *Bam*HI or *Sal*I restriction site for cloning into the corresponding sites of YeGFP-His or YDsRed-LEU.

Underlined sequence designates the homologous complementary sequence.

Table 15. Organophosphate Degrading Enzymes

Species/source	Gene name/abbreviation	Enzyme name	Genbank accession number
<i>Flavobacterium</i>	Organophosphate degrading (opd)	Organophosphorus hydrolase (OPH)	M29593
<i>Pseudomonas diminuta</i>	opd	Phosphotriesterase	AY766084
<i>Agrobacterium tumefaciens</i>	opdA	OpdA	M20392
<i>Alteromonas</i>	OpaA	Organophosphorus acid anhydrolase (OPAA)	AY043245
<i>Loligo vulgaris</i> (squid)		DFPase	ASU29240
Mammalian	PON	Paraoxonase (PON)	U56398
			NM 000446
			NM 001013082
			NM 032077
			NM 183308
			NM 173006
			NM 011134
			NM 000940
			XM 418669

Table 16. Organophosphate degrading enzymes hydrolyze (detoxify) different bonds within the different organophosphates

Enzyme	Bond cleaved by enzyme				
	P-C	P-O	P-F	P-S	P-CN
OPH		+	+	+	+
OPAA	-	+	+	-	+
PON	+	+	+		+
DFPase		-	+		-

Table 17. OPH cleaves the following organophosphate nerve agents and pesticides by hydrolyzing the designated bond.

Organophosphate	Bond type
Nerve agent	
VX	P-S
Sarin	P-F
Soman	P-F
Tabun	P-CN
Pesticide	
Paraoxon	P-O
DFP*	P-F
Parathion	P-O
Methyl parathion	P-O
Coumaphos	P-O
Diazinon	P-O
Fensulfothion	P-O
Acephate	P-S
Demeton-S	P-S
Phosalone	P-S
Malathion	P-S

* DFP, diisopropyl fluorophosphate

WHAT IS CLAIMED IS:

1. A yeast biosensor, said biosensor comprising:

a first expression control sequence operably linked to a first nucleic acid encoding a first reporter, wherein said first expression control sequence drives
5 expression of the first reporter if an organophosphate is present;

a second expression control sequence operably linked to a second nucleic acid encoding a second reporter, wherein said second expression control sequence drives expression of the second reporter if an organophosphate hydrolytic product is present;
and

10 at least one enzyme that hydrolyzes the organophosphate to produce the organophosphate hydrolytic product.

2. A yeast biosensor according to claim 1, wherein the first reporter is selected from the group consisting of enhanced green fluorescent protein, yeast
15 enhanced green fluorescent protein, *Aequorea coerelescens* green fluorescent protein, DsRed monomer, DsRed2, DsRed express, RedStar2, ASRed2, HcRed1, AmCyan1, ZsYellow1, ZsGreen1, and/or AmCyan1, insect luciferase, bacterial luciferase, bacterial bioluminescence, Renilla luciferase, uroporphyrinogen III methyltransferase, secreted alkaline phosphatase, β -galactosidase, β -glucuronidase, an ice nucleation
20 protein, and combinations thereof.

3. A yeast biosensor according to claim 1, wherein the second reporter is selected from the group consisting of enhanced green fluorescent protein, yeast enhanced green fluorescent protein, *Aequorea coerelescens* green fluorescent protein,
25 DsRed monomer, DsRed2, DsRed express, RedStar2, ASRed2, HcRed1, AmCyan1, ZsYellow1, ZsGreen1, and/or AmCyan1, insect luciferase, bacterial luciferase, bacterial bioluminescence, Renilla luciferase, uroporphyrinogen III methyltransferase, secreted alkaline phosphatase, β -galactosidase, β -glucuronidase, an ice nucleation protein, and combinations thereof.

30

4. A yeast biosensor according to claim 1, wherein the first and second reporters are different from each other.

5. A yeast biosensor according to claim 1, wherein the first expression control sequence comprises nucleotides -500 to -1 of a gene selected from the group consisting of Accession No. YGR035C, Accession No. YHR139C, Accession No. YOR186W, Accession No. YGR213C, Accession No. YLR346C, Accession No. YIR017C, and Accession No. YLL056C.

6. A yeast biosensor according to claim 1, wherein the first expression control sequence comprises nucleotides -1000 to -1 of a gene selected from the group consisting of Accession No. YGR035C, Accession No. YHR139C, Accession No. YOR186W, Accession No. YGR213C, Accession No. YLR346C, Accession No. YIR017C, and Accession No. YLL056C.

7. A yeast biosensor according to claim 1, wherein the second expression control sequence comprises nucleotides -500 to -1 of a gene selected from the group consisting of Accession No. YGL205W, Accession No. YJL219W, Accession No. YGR287C, and Accession No. YHL012W.

8. A yeast biosensor according to claim 1, wherein the second expression control sequence comprises nucleotides -1000 to -1 of a gene selected from the group consisting of Accession No. YGL205W, Accession No. YJL219W, Accession No. YGR287C, and Accession No. YHL012W.

9. A yeast biosensor according to claim 1, wherein the at least one enzyme is selected from the group consisting of organophosphorus hydrolase (OPH), phosphotriesterase, OpdA, organophosphorus acid anhydrolase (OPAA), DFPase, and paraoxonase (PON).

10. A yeast biosensor according to claim 1, wherein the at least one enzyme is intracellular.

11. A yeast biosensor according to claim 1, wherein the yeast biosensor comprises a mutation in ergosterol biosynthetic gene.

12. A method of identifying a yeast gene that is upregulated by an organophosphate, said method comprising:

contacting a yeast with the organophosphate;

collecting RNA from the yeast;

contacting the RNA with a yeast microarray having feature loci that correspond to yeast genes under conditions that permit hybridization of complimentary sequences;

comparing a metric of the hybridization at each feature locus with the same metric of hybridization at a corresponding feature locus for RNA from yeast not contacted with the organophosphate;

identifying a feature locus where the hybridization metric is higher for the yeast contacted with the organophosphate than the yeast not contacted with the organophosphate; and

correlating the identified feature locus with its respective yeast gene.

13. A method of preparing a yeast biosensor that is sensitive to an organophosphate, said method comprising:

identifying a yeast gene that is upregulated by an organophosphate;

identifying at least one expression control sequence of the identified gene;

operably linking a nucleic acid comprising the expression control sequence to a nucleic acid encoding a reporter selected from the group consisting of YeGFP, YDsRed, luxAB; and

contacting the operably linked nucleic acids with a cell under conditions that permit uptake of the nucleic acids.

14. A method according to claim 13, wherein the operably linked nucleic acids are comprised in a yeast plasmid.

15. A method according to claim 13, wherein uptake of the operably linked nucleic acids comprises integration of at least one copy of the operably linked nucleic acids into a chromosome.

5 16. A method according to claim 13, wherein the expression control sequence comprises nucleotides -500 to -1 of the identified gene.

17. A method of identifying a yeast gene that is upregulated by an organophosphate hydrolytic product, said method comprising:

10 contacting a yeast with the organophosphate hydrolytic product;

 collecting RNA from the yeast;

 contacting the RNA with a yeast microarray having feature loci that correspond to yeast genes under conditions that permit hybridization of complementary sequences;

15 comparing a metric of the hybridization at each feature locus with the same metric of hybridization at a corresponding feature locus for RNA from yeast not contacted with the organophosphate hydrolytic product;

 identifying a feature locus where the hybridization metric is higher for the yeast contacted with the organophosphate hydrolytic product than the yeast not
20 contacted with the organophosphate hydrolytic product; and

 correlating the identified feature locus with its respective yeast gene.

18. A method of identifying a yeast gene that is upregulated by organophosphate hydrolysis, said method comprising:

25 contacting a recombinant OPH⁺ yeast with an organophosphate under conditions that permit organophosphate hydrolysis;

 collecting RNA from the recombinant OPH⁺ yeast;

 contacting the subtracted RNA with a yeast microarray having feature loci that correspond to yeast genes under conditions that permit hybridization of
30 complementary sequences;

comparing a metric of the hybridization at each feature locus with the same metric of hybridization at a corresponding feature locus for RNA from yeast lacking OPH contacted with the organophosphate;

identifying a feature locus where the hybridization metric is higher for the recombinant OPH⁺ yeast contacted with the organophosphate than the yeast lacking OPH contacted with the organophosphate; and

correlating the identified feature locus with its respective yeast gene.

19. A method of preparing a yeast biosensor that is sensitive to an organophosphate hydrolytic product, said method comprising:

identifying a yeast gene that is upregulated by an organophosphate hydrolytic product;

identifying at least one expression control sequence of the identified gene;

operably linking a nucleic acid comprising the expression control sequence to a nucleic acid encoding a reporter selected from the group consisting of enhanced green fluorescent protein, yeast enhanced green fluorescent protein, *Aequorea coerelescens* green fluorescent protein, DsRed monomer, DsRed2, DsRed express, RedStar2, ASRed2, HcRed1, AmCyan1, ZsYellow1, ZsGreen1, and/or AmCyan1, insect luciferase, bacterial luciferase, bacterial bioluminescence, Renilla luciferase, uroporphyrinogen III methyltransferase, secreted alkaline phosphatase, β -galactosidase, β -glucuronidase, an ice nucleation protein, and combinations thereof;

contacting the operably linked nucleic acids with a cell under conditions that permit uptake of the nucleic acids.

20. A method according to claim 19, wherein the operably linked nucleic acids are comprised in a yeast plasmid.

21. A method according to claim 19, wherein uptake of the operably linked nucleic acids comprises integration of at least one copy of the operably linked nucleic acids into a chromosome.

22. A method according to claim 19 wherein the expression control sequence comprises nucleotides -500 to -1 of the identified gene.

23. A method of preparing a yeast biosensor that is sensitive to an organophosphate and a hydrolytic product of the organophosphate, said method comprising:

identifying a yeast gene that is upregulated by an organophosphate;

identifying at least one expression control sequence of the identified organophosphate-sensitive gene;

10 operably linking a nucleic acid comprising the organophosphate expression control sequence to a nucleic acid encoding a first reporter selected from the group consisting of enhanced green fluorescent protein, yeast enhanced green fluorescent protein, *Aequorea coerelescens* green fluorescent protein, DsRed monomer, DsRed2, DsRed express, RedStar2, ASRed2, HcRed1, AmCyan1, ZsYellow1, ZsGreen1, 15 and/or AmCyan1, insect luciferase, bacterial luciferase, bacterial bioluminescence, Renilla luciferase, uroporphyrinogen III methyltransferase, secreted alkaline phosphatase, β -galactosidase, β -glucuronidase, an ice nucleation protein, and combinations thereof;

contacting the operably linked organophosphate nucleic acids with a cell under 20 conditions that permit uptake of the nucleic acids;

identifying a yeast gene that is upregulated by a hydrolytic product of the organophosphate;

identifying at least one expression control sequence of the identified organophosphate hydrolytic product-sensitive gene;

25 operably linking a nucleic acid comprising the organophosphate hydrolytic product expression control sequence to a nucleic acid encoding a second reporter selected from the group consisting of enhanced green fluorescent protein, yeast enhanced green fluorescent protein, *Aequorea coerelescens* green fluorescent protein, DsRed monomer, DsRed2, DsRed express, RedStar2, ASRed2, HcRed1, AmCyan1, 30 ZsYellow1, ZsGreen1, and/or AmCyan1, insect luciferase, bacterial luciferase, bacterial bioluminescence, Renilla luciferase, uroporphyrinogen III methyltransferase,

secreted alkaline phosphatase, β -galactosidase, β -glucuronidase, an ice nucleation protein, and combinations thereof; and

contacting the operably linked organophosphate hydrolytic product nucleic acids with a cell under conditions that permit uptake of the nucleic acids,

5 wherein the nucleic acids encoding the first and second reporters are different from each other.

24. A method according to claim 23, wherein the operably linked organophosphate nucleic acids are comprised in a yeast plasmid.

10

25. A method according to claim 23, wherein the operably linked organophosphate hydrolytic product nucleic acids are comprised in a yeast plasmid.

26. A method according to claim 23, wherein uptake of the operably linked organophosphate nucleic acids comprises integration of at least one copy of the operably linked organophosphate nucleic acids into a chromosome.

15

27. A method according to claim 23, wherein uptake of the operably linked organophosphate hydrolytic product nucleic acids comprises integration of at least one copy of the operably linked organophosphate hydrolytic product nucleic acids into a chromosome.

20

28. A method according to claim 23, wherein the organophosphate expression control sequence comprises nucleotides -500 to -1 of the identified organophosphate-sensitive gene.

25

29. A method according to claim 23, wherein the organophosphate hydrolytic product expression control sequence comprises nucleotides -500 to -1 of the identified organophosphate hydrolytic product-sensitive gene.

30. A method of preparing a yeast biosensor that is sensitive to hydrolysis of an organophosphate, said method comprising:

identifying a yeast gene that is upregulated by hydrolysis of an organophosphate;

5 identifying at least one expression control sequence of the identified gene;

operably linking a nucleic acid comprising the expression control sequence to a nucleic acid encoding a reporter selected from the group consisting of enhanced green fluorescent protein, yeast enhanced green fluorescent protein, *Aequorea coerelescens* green fluorescent protein, DsRed monomer, DsRed2, DsRed express, RedStar2, ASRed2, HcRed1, AmCyan1, ZsYellow1, ZsGreen1, and/or AmCyan1, insect luciferase, bacterial luciferase, bacterial bioluminescence, Renilla luciferase, uroporphyrinogen III methyltransferase, secreted alkaline phosphatase, β -galactosidase, β -glucuronidase, an ice nucleation protein, and combinations thereof;

10 contacting the operably linked nucleic acids with a cell under conditions that permit uptake of the nucleic acids.

31. A method of preparing a yeast biosensor that is sensitive to an organophosphate and hydrolysis of the organophosphate, said method comprising:

identifying a yeast gene that is upregulated by an organophosphate;

20 identifying at least one expression control sequence of the identified organophosphate-sensitive gene;

operably linking a nucleic acid comprising the organophosphate expression control sequence to a nucleic acid encoding a first reporter selected from the group consisting of enhanced green fluorescent protein, yeast enhanced green fluorescent protein, *Aequorea coerelescens* green fluorescent protein, DsRed monomer, DsRed2, DsRed express, RedStar2, ASRed2, HcRed1, AmCyan1, ZsYellow1, ZsGreen1, and/or AmCyan1, insect luciferase, bacterial luciferase, bacterial bioluminescence, Renilla luciferase, uroporphyrinogen III methyltransferase, secreted alkaline phosphatase, β -galactosidase, β -glucuronidase, an ice nucleation protein, and combinations thereof;

30 contacting the operably linked organophosphate nucleic acids with a cell under conditions that permit uptake of the nucleic acids;

identifying a yeast gene that is upregulated by hydrolysis of the organophosphate;

identifying at least one expression control sequence of the identified organophosphate hydrolytic product-sensitive gene;

5 operably linking a nucleic acid comprising the organophosphate hydrolytic product expression control sequence to a nucleic acid encoding a second reporter selected from the group consisting of enhanced green fluorescent protein, yeast enhanced green fluorescent protein, *Aequorea coerelescens* green fluorescent protein, DsRed monomer, DsRed2, DsRed express, RedStar2, ASRed2, HcRed1, AmCyan1,
10 ZsYellow1, ZsGreen1, and/or AmCyan1, insect luciferase, bacterial luciferase, bacterial bioluminescence, Renilla luciferase, uroporphyrinogen III methyltransferase, secreted alkaline phosphatase, β -galactosidase, β -glucuronidase, an ice nucleation protein, and combinations thereof; and

contacting the operably linked organophosphate hydrolytic product nucleic
15 acids with a cell under conditions that permit uptake of the nucleic acids,

wherein the nucleic acids encoding the first and second reporters are different from each other.

1/18




FIG.1




FIG.2




FIG.3

3/18

Yeast codon-optimized opd sequence

ATGACTATGATAACTAACAGCGGCGACAGGATAAACACAGTACGAGGACCAATTACTATATCCGAAGCAGGATT
CACACTGACCCATGAACATATTTGTGGATCGTCAGCAGGGTTTTTAAGAGCTTGGCCCGAGTTCTTTGGCTCAA
GAAAGGCGTTAGCAGAGAAAAGCCGTAAGGGGATTGCGAAGAGCTAGAGCCGCCGGTGTTAGAACCATTGTTGAC
GTTTCTACATTGATATCGGAAGGGACGTTTCTCTACTAGCGGAAGTCTCCAGGGCTGCGGACGTGCATATTGT
TGCTGCCACTGGTCTATGGTTTGATCCTCCATTGTCAATGAGGTTGAGATCAGTGGAGGAACTTACGCAATTTT
TCTTGCGTGAGATTCAATACGGTATAGAAGACACAGGTATTAGAGCAGGTATCATCAAAGTAGCTACAACCGGG
AAGGCTACTCCTTTTCAAGAATTAGTTCTAAA. AGCCGCAGCCAGGGCATCCCTTGCTACCGGTGTTCTGTGA
CAACTCATACGGCTGCCTCTCAGCGTGATGGCGAACAACAAGCTGCTATCTTTGAAAGCGAAGGCTTGCGCCA
AGTAGAGTGTGTATTGGACATTCTGATGATACTGATGACTTGTCTTACTTGACCGCATTAGCTGCCAGAGGTTA
TTTAATAGGTTTGGACCACATTCCTCACAGTGCAATTGGTTTGGAGGATAATGCATCGGCTAGTGCTCTGTTAG
GGATTGCGAGTTGGCAGACTAGGGCTCTGCTAATAAAGGCATTAATTGACCAAGGGTATATGAAACAGATCCTT
GTTTCAAATGATTGGCTTTTCGGTTTTTCATCTTATGTAACATAATATCATGGATGTAATGGATCGCGTCAATCC
AGACGGTATGGCTTTCATTCCGTTACGTGTCATACCGTTTCTGCGTGAAAAAGGCGTCCCCCAGGAAACGTTGG
CAGGTATTACTGTTACAAACCCAGCCAGATTTTAAAGCCCTACGCTCAGAGCCTCCTGA

FIG.4A

Yeast codon-optimized DsRed express sequence

ATGGCTAGCTCCGAGGACGTTATAAAAGAGTTCATGAGATTTAAAGTAAGAATGGAGGGCAGTGTTAACGGTCA
CGAATTTGAAATAGAAGGGGAAGGCGAGGGTAGACCATATGAAGGCACTCAAACAGCCAA. ACTGAAGGTTACT
AAGGGAGGTCCATTGCCTTTTGCATGGGATATTTTGTCCCCTCAATTTCAATACGGGAGTAAAGTGATGTGAA
ACACCCCGCTGACATCCCTGATTATAAGAACTCTCTTTTCCAGAAGGATTCAAGTGGGAAAGAGTCATGAAC
TCGAAGACGGAGGTGTAGTAACGGTAACCCAGGATTCTTCTCTTCAAGATGGTAGCTTTATCTATAAGGTTAAA
TTCATTGGAGTCAATTTCCATCAGACGGTCCCGTTATGCAGAAGAAAATATGGGATGGGAAGCCTCGACAGA
GAGGTTGTATCCGCGTGATGGGGTGTGAAAGGCGAAATTCATAAGGCTTTAAAGTTAAAGACGGTGGTCATT
ATTTAGTTGAATTCAAATCTATTTACATGGCGAAAAAGCCTGTCCAATTACCAGGTTACTACTACGTGGATTCA
AACTAGATATTACCTCACATAATGAGGATTATACAATCGTGAACAATACGAACGAGCAGAAGGCAGGCATCA
TCTTTTTCTATAG

FIG.4B




FIG.5




FIG.6

6/18

6/18




FIG. 7A




FIG. 7B

7/18

7/18




FIG.8




FIG. 9A

FIG. 9B

FIG. 9C




FIG.10B




FIG.10A

10/18

10/18




FIG.11




FIG.12




FIG.13

12/18

12/18




FIG. 14

YGR035C-FI-YeGFP sequence

gtcgaCAGAGTTTACTTGCCTACCACAATTTAGATCAAGTAATCGTGGGATTGAGCGTGGGGGCACTGACTGG
ATCACTTTATTTTTTATAGTTGGCATCATAAGAGAGCTTGGTTTAATCAATTGGTTTTTAAACTACGTATTG
TCAGATTATTTACATGACAGATTCTTACAATCTGGCGCCTTTGACATTGAAAGAGAATTACGAGGCGTATTGG
AAAAGAATAAATCAGCGATCTTTCAATGATAAATCCAAAAGGGATTAGGTTGAACATTTCATTTTCTTATTTT
TTTCTCATAAAGAAAGCCGAAAGCCTGCTCTCTACAGTTATTAATTAAGAACGCTCGTTTTAAACAGTTACTG
TGTAAAGCGACGGTAATCGAAAAAGTATGTGACATCGTGCAAAAGAAGATAATCAAAACCATGCAGAACGTAGA
ATAAATGTGAGTTCTATCACTTGCAGAGATAATACCTCTGACGCCGCGGGGCCGATTGTTCCACGGAGGGAAA
GAATCGGCCCTCGGGTTTTACGAGAGCGCCGCGGGTGAACCTCACTTTTTCTCGAGAAGAAGTTTCTACGGCA
GAATAAGACCTTTTCCACGGATAATCAGCGGAGCTTCTGGACATAATAGATGGTTTGTAAAAAGCTTAAGGA
AAGCCGCGGATTTAGCATGTCACCCACACTTAGATTACGAAAGCAAGGATTGCAGAAAAAAGATGAGATACAG
TTTTGAGGGCAATATATAAAATATATAAATATAGCAACATTCCTTCTCTCTGTTATGTCCACAATACTTCTAA
AAGTTGTAACATATATCTATACATAAAACTTGTAAACAAACATATAATTAACAACAAGTAGTGACAAGACGGAAG
TTATAAGTTATCTTCTCTACAGAAACAATACGTAggatccattaaaATGTCTAAAGGTGAAGAATTATTCAGTG
GTGTTGTCCCAATTTTGGTTGAATTAGATGGTGATGTTAATGGTCACAAATTTTCTGTCTCCGGTGAAGGTGAA
GGTGATGCTACTTACGGTAAATTGACCTTAAATTTATTTGTACTACTGGTAAATTGCCAGTTCCATGGCCAAC
CTTAGTCACTACTTTCGGTTATGGTGTTCATGTTTTGCGAGATACCCAGATCATATGAAACAACATGACTTTT
TCAAGTCTGCCATGCCAGAAGGTTATGTTCAAGAAAGAACTATTTTTTCAAAGATGACGGTAACTACAAGACC
AGAGCTGAAGTCAAGTTTGAAGGTGATACCTTAGTTAATAGAATCGAATTAAGGTATTGATTTTAAAGAAGA
TGGTAACATTTTAGGTCACAAATTGGAATACAACATAACTCTCACAATGTTTACATCATGGCTGACAAACAAA
AGAATGGTATCAAAGTTAACTTCAAAATTAGACACAACATTGAAGATGGTTCTGTTCAATTAGCTGACCATTAT
CAACAAAATACTCCAATTGGTGATGGTCCAGTCTTGTTACCAGACAACCATTACTTATCCACTCAATCTGCCTT
ATCCAAAGATCCAAACGAAAAGAGAGACCACATGGTCTTGTTAGAATTTGTTACTGCTGCTGGTATTACCCATG
GTATGGATGAATTGTACAAATAAactagt

FIG.15A

[illegible]

FIG. 15B

15/18




FIG.16




FIG.17

pYGR287C-FI-YDsRed

gtcgacGGCTGTATGTTTATGATTGCTCGAATCACGTTTTCTTGTTTTTCGTCAAGAATTCCAGTCAAGTTT
TCCACCACCTTGACCCTTAAAGCATCGACTTTTGTGCTCTTGAATGTGTTTCTAAGAATACTTGTAAGGACAC
CCTCTAATTTTGTGTGCACTTTTCACATATTATCAAGACAATCGTTCCTGTACTCAGATGCACTGTTACTGTAA
AGACTACTATACAACAAGCGAAAAATGATGTTTCGAAAACCTTTATTTCTATTTTGAAAGGCATGTGTCTCGAGG
TCCTTGCTTTATTGTGGGTGGTCATGCCATTCTGTAAACCTTACGGTACTGCTCCGCTATATCTTTGAGGTTG
TTATTTCCCCACAAATATGCGTTTCTAACCGAATATTCATTCACTCGGACCGGACAATAGCTCTTAAGTGCCTT
TACCGGAGTAAATATCGTAAGAATTTGCATGCGGTGAAATACAGGGAAAAATAAGAAATTACACCCTAATACAAA
AAGAAAACTAAGTTTCACAATACGTAAGGATATTTTGTGGGGAGAATATTTTCGGAGAATAAAGTTTCCAAGTC
CGCGGTGTGAACAACCGCTCAGCACGCAGCGTTATTTCTCGAGAAAAGTGGCCCTGAAATAAGGAAAAAAGTTA
CTAATGTTTTTTCGCTGTACGATATCAAATGTGACGAAGTAGGCACCCACGCTATAAATTGGCTACTAAAGTT
TATGTCAGTACTTGGGATCGTTGAAATACTCGGATAAATTATGTTCCCTTATTTTTCATGGTTTTTCGTCATACCA
CAGTTTACCCAGAAATGAGAAAGGATCTCCTTTTGAATAAAAAAGTACTTAAGGGCAATGATATTGAGTTGCTA
GACGTTTGGTTAGACGCCTGTTTTGAAATAAAAAAGCTGTCTCAAATTAATCGAGCAAGCACAGATCAAACAAG
ATACAAACAAAGCTTTTCAACGTAATATTTACTATCGgatccaaaagtATGGCTAGCTCCGAGGACGTTATAAA
AGAGTTCATGAGATTTAAAGTAAGAATGGAGGGCAGTGTTAACGGTCACGAATTTGAAATAGAAGGGGAAGGCG
AGGGTAGACCATATGAAGGCACTCAAACAGCCAACTGAAGGTTACTAAGGGAGGTCCATTGCCTTTTGCATGG
GATATTTTGTCCCCTCAATTTCAATACGGGAGTAAAGTGTATGTGAAACACCCCGCTGACATCCCTGATTATAA
GAACTCTCTTTTCCAGAAGGATTCAAGTGGGAAAGAGTCATGAACCTCGAAGACGGAGGTGTAGTAACGGTAA
CCCAGGATTCTTCTCTTCAAGATGGTAGCTTTATCTATAAGGTAAATTCATTGGAGTCAATTTTCCATCAGAC
GGTCCCGTTATGCAGAAGAACTATGGGATGGGAAGCCTCGACAGAGAGGTGTATCCGCGTGATGGGGTGT
GAAAGGCGAAATTCATAAGGCTTTAAAGTTAAAGACGGTGGTCATTATTTAGTTGAATTCAAATCTATTTACA
TGGCGAAAAAGCCTGTCCAATTACCAGGTTACTACTACGTGGATTCAAACCTAGATATTACCTCACATAATGAG
GATTATACAATCGTCGAACAATACGAACGAGCAGAAGGCAGGCATCATCTTTTCTATAGgcggccgc

FIG. 18A

17/18

pPOX1-FI-YDsRed

gtcgacTTTCACTCAACCACCTCCAAAAATAACAGGTTATCTAAAGTAAAAGACTTTAACTTGCTCTTAGTT
TCCAAATTAATATCTGCACGATAGTACCATTTGCTCTAACGGAAATAACCATCTGAGATGGATGCATGATAGC
AGAATCACCGCCCATATTCTTCCTTGCTACTTCATTGCCTTTGGCCAAATCCACGATTGCAACAGAGTTTGTAC
CGTCCTTTGTTTCTCTAACAGTGACGAAGTGGTCACTCTCGAAAGTAGTTGATCTGAAGTCAAGGAATTGAGGG
GAAATTCCTAAGGACATCAGATCGACCAATTCGGTAAATCAATGGGTAGGTCACTCATTGGTTAGAACTTTG
TGATAATTTATTTTTATAGTTGAATATCTTCTTCTCTCAACTCTGATCCGGATTGTCGAGGTTTCAATAAG
TACTCTGAACAATAATCAAAATATCTCCTTATTTCTGTAGATTCCTTCAGTTCCACTTTTTACTTTTCTTAA
TTCTCTTTGTATTTATTCCTAGCGACGAAAAATGCGAGATCTCGACCAAAAAAGGGGGTAGGGTAATAAAATT
AACCTATTATTTTTAACTTTAAACCTATAATGTGCTAATATTTTATTATAAACCTCCTTTTTTTCGCTTCA
AACCTGACACATTTTAAGCCCTATATTTACGGTATTAGTTGATTAACTCCGAAGCGAAAGGAATTCGGTCAT
TAGCGGCTAATAGCCGTTGGGGTAAATCACCTACAAGCAAGTACACAAGAGAACGTTGGCGTTGTTAAGTCAAA
GCACTAATACATTGGGGCTTTAAGAGTGTATAAAGGTCTAACCTGTAAAAATTATTTAAACAACCTGAACAG
GCCTTAAAGTTTTCTCATTCCGCTCATCATCACTAATATTGCTCTCCGTTTTTTGAATACACACTTGACACTAA
TAAGTATCACAGAAAAAAGAAAATATAATAAATTAGTATTGCGATggatccaaaagtATGGCTAGCTCCGAGG
ACGTTATAAAAAGAGTTCATGAGATTTAAAGTAAGAATGGAGGGCAGTGTTAACGGTCACGAATTTGAAATAGAA
GGGGAAGGCGAGGGTAGACCATATGAAGGCACTCAAACAGCCAACTGAAGGTTACTAAGGGAGGTCCATTGCC
TTTTGCATGGGATATTTTGTCCCTCAATTTCAATACGGGAGTAAAGTGTATGTGAAACACCCCGCTGACATCC
CTGATTATAAGAACTCTCTTTCCAGAAGGATTCAAGTGGGAAAGAGTCATGAACTTCGAAGACGGAGGTGTA
GTAACGGTAACCCAGGATTCTTCTTTCAAGATGGTAGCTTTATCTATAAGGTTAAATTCATTGGAGTCAATTT
TCCATCAGACGGTCCCGTTATGCAGAAGAAAACTATGGGATGGGAAGCCTCGACAGAGAGGTTGTATCCGCGTG
ATGGGGTGTGTGAAAGGCGAAATTCATAAGGCTTTAAAGTTAAAAGACGGTGGTCATTATTTAGTTGAATTCAAA
ICTATTTACATGGCGAAAAAGCCTGTCCAATTACCAGGTTACTACTACGTGGATTCAAACTAGATATTACCTC
ACATAATGAGGATTATACAATCGTCGAACAATACGAACGAGCAGAAGGCAGGCATCATCTTTTTCTATAGgcgg
ccgc

FIG.18B

18/18




FIG.19




FIG.20

SEQUENCE LISTING

<110> Guild Associates, Inc.
 Schofield, David A. et al.

<120> DIFFERENTIALLY FLUORESCENT YEAST BIOSENSORS FOR THE DETECTION AND
 BIODEGRADATION OF CHEMICAL AGENTS

<130> 068343.0131

<150> US 60/740,887
 <151> 2005-11-30

<160> 48

<170> PatentIn version 3.3

<210> 1
 <211> 1020
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Synthetic Yeast codon-optimized opd sequence

<400> 1
 atgactatga taactaacag cggcgacagg ataaacacag tacgaggacc aattactata 60
 tccgaagcag gattcacact gacccatgaa catatttgtg gatcgtcagc aggggttttta 120
 agagcttggc ccgagttctt tggctcaaga aaggcgttag cagagaaagc cgtaagggga 180
 ttgcgaagag ctagagccgc cgggtgtaga accattgttg acgtttctac attcgatattc 240
 ggaagggacg tttctctact agcggaaagtc tccagggctg cggacgtgca tattgttgct 300
 gccactggtc tatggtttga tcttccattg tcaatgaggt tgagatcagt ggaggaactt 360
 acgcaatfff tcttgcgtga gattcaatac ggtatagaag acacaggtat tagagcaggt 420
 atcatcaaag tagctacaac cgggaaggct actccttttc aagaattagt tctaaaagcc 480
 gcagccaggg catcccttgc taccggtgtt cctgtgacaa ctcatagcgc tgcctctcag 540
 cgtgatggcg aacaacaagc tgctatcttt gaaagcgaag gcttgtcgcc aagtagagtg 600
 tgtattggac attctgatga tactgatgac ttgtcttact tgaccgcatt agctgccaga 660
 ggttatttaa taggtttgga ccacattccc cacagtgcaa ttggtttgga ggataatgca 720
 tcggctagtg ctctgttagg gattcgcagt tggcagacta gggctctgct aataaaggca 780
 ttaattgacc aagggtatat gaaacagatc cttgtttcaa atgattggct tttcggtttt 840
 tcatcttatg taactaatat catggatgta atggatcgcg tcaatccaga cggataggct 900
 ttcatccgt tacgtgtcat accgtttctg cgtgaaaaag gcgtcccca ggaaacgttg 960
 gcaggtatta ctgttacaaa ccagccaga tttttaagcc ctacgctcag agcctcctga 1020

<210> 2
 <211> 678

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Yeast codon-optimized DsRed express sequence

<400> 2

```

atggctagct ccgaggacgt tataaaagag ttcattgagat ttaaagtaag aatggagggc      60
agtgttaacg gtcacgaatt tgaaatagaa ggggaaggcg agggtagacc atatgaaggc      120
actcaaacag ccaaactgaa gggtactaag ggaggtccat tgccttttgc atgggatatt      180
ttgtcccctc aatttcaata cgggagtaaa gtgtatgtga aacaccccg c tgacatccct      240
gattataaga aactctcttt tccagaagga ttcaagtggg aaagagtcatt gaacttcgaa      300
gacggagggtg tagtaacggt aaccaggat tcttctcttc aagatggtag ctttatctat      360
aagggttaaat tcattggagt caattttcca tcagacgggc ccgttatgca gaagaaaact      420
atgggatggg aagcctcgac agagaggttg tatccgcgtg atgggggtgtt gaaaggcgaa      480
attcataagg ctttaaagtt aaaagacggt ggtcattatt tagttgaatt caaatctatt      540
tacatggcga aaaagcctgt ccaattacca gggtactact acgtggattc aaaactagat      600
attacctcac ataatgagga ttatacaatc gtcgaacaat acgaacgagc agaaggcagg      660
catcatcttt ttctatag                                     678

```

<210> 3

<211> 1731

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic nucleotide derived from E. coli and S. cerevisiae

<400> 3

```

gtcgacagag tttacttgca ctaccacaat ttagatcaag taatcgtggg attcagcgtg      60
ggggcactga ctggatcact ttattttttt atagttggca tcataagaga gcttggttta      120
atcaattggt ttttaaaact acgtattgtc agattattttt acatgacaga ttcttacaat      180
ctggcgccct tgacattgaa agagaattac gaggcgtatt ggaaaagaat aaatcagcga      240
tctttcaatg ataaatccaa aagggaattag gttgaacatt tcatttttct tattttttca      300
tctatttttag cgaggcgatc ttgagcgttt gtgtaactgg ataaaacttg gcaagctgga      360
gtagtcctta tttctcataa agaaagccga aagcctgctc tcctacagtt attaattaag      420
aacgctcgtt ttaaacagtt actgtgtaaa gcgacggtaa tcgaaaaagt atgtgacatc      480
gtgcaaaaga agataatcaa aacatgcag aacgtagaat aaatgtgagt tctatcactt      540
gcggagataa taccctctga cgccgcgggg ccgattgttc cacggaggga aagaatcggc      600
cctcgggttt tacgagagcg ccgcgggtga actcactttt ttctcgagaa gaagtttcct      660

```

```

acggcagaat aagacccttt tccacggata atcagcggag cttctggaca taatagatgg 720
tttgtgaaaa agcttaagga aagccgcgga tttagcatgt caccacact tagattacga 780
aagcaaggat tgcagaaaaa aagatgagat acagttttga gggcaatata taaaatatat 840
aaatatagca acattcccctt ctctctgtta tgtccacaat acttctaaaa gttgtaacat 900
atatctatac ataaaaactt gtaacaaaca tataattaaa acaactagtg acaagacgga 960
agttataagt tatcttctct acagaaacaa tacgtaggat ccattaaaat gtctaaaggt 1020
gaagaattat tctactggtgt tgtcccaatt ttggttgaat tagatggtga tgttaatggt 1080
cacaaatttt ctgtctccgg tgaagggtgaa ggtgatgcta cttacggtaa attgacctta 1140
aaatttattt gtactactgg taaattgcc a gttccatggc caaccttagt cactactttc 1200
ggttatggtg ttcaatgttt tgcgagatac ccagatcata tgaaacaaca tgactttttc 1260
aagtctgcca tgccagaagg ttatgttcaa gaaagaacta tttttttcaa agatgacggt 1320
aactacaaga ccagagctga agtcaagttt gaagggtgata ccttagttaa tagaatcgaa 1380
ttaaaaggta ttgattttta agaagatggt aacatttttag gtcacaaatt ggaatacaac 1440
tataactctc acaatgttta catcatggct gacaaacaaa agaatggtat caaagttaac 1500
ttcaaaaatta gacacaacat tgaagatggt tctgttcaat tagctgacca ttatcaacaa 1560
aatactcaa ttggtgatgg tccagtcttg ttaccagaca accattactt atccactcaa 1620
tctgccttat ccaaagatcc aaacgaaaag agagaccaca tggctctggt agaatttggt 1680
actgctgctg gtattacca tggtatggat gaattgtaca aataaactag t 1731

```

<210> 4
 <211> 1714
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Synthetic nucleotide derived from *E. coli* and *S. cerevisiae*

```

<400> 4
gtcgactttc ttcttttctt actatcttct cttttattat tatattatat tatcaataac 60
cctcatctct ctctctctct ctctctctct ctctctctct ctctctctct ctctctctct 120
ctctctctcc ttttttctt ctttttagatt tttttgcttt tgtttaattt cattccagtt 180
tcccccccc aatattaata ttcgttccta gagcctatca cacctaatat ttcccgata 240
cattatagta aatacctcaa gacacttatg atagatTTTT ttccttaact caaacctaact 300
tagctctatg cataaagaaa gttttgaata aggaaatccg catattcaaa ttatcaaaca 360
tgcaattcat ctgcaaaact tccaaaaact ttctgctcgt taatagtcaa tgtatggtaa 420
tgcaatgag caggtagccc ttattataat gattaatact tacatcatag ttaataatct 480
tatctcaggg taccataat ttcaaccatc cttagcttcc attaaaaaca caatgagttg 540

```

```

cgttactagc gaagcggcctt atctgttaat tcttgcttgc aaacatctta gctgaaagtg    600
aaaaggcaca gccgcacctg ctgaatgctc aacgtttgta ataatccgcc tatttccgcg    660
gaatcaatag ggctcctagc aggccgccat caattttcag cgtgccgcat taaaattata    720
ttaccaagat ttccattttcc gcggctgatt cctatcaata ttaagtaatc aatcttttcc    780
tcgtgattct ttgtgatgct cattcacaga ggactaatta agacatgtag cacaatatat    840
tcatataaaa gttggtgcag ttaatgatta attgcattgt tttccttggt tctttctggt    900
atacctgtcg aattaaacat aaagtgtata tgaattttta ggggcacaaa taacaaagga    960
ttatttatca cttttaatag gatccattaa aatgtctaaa ggtgaagaat tattcactgg   1020
tgttgtccca attttggttg aattagatgg tgatgttaat ggtcacaaat tttctgtctc   1080
cgggtgaaggt gaaggtgatg ctacttacgg taaattgacc ttaaaattta tttgtactac   1140
tggtaaattg ccagttccat ggccaacctt agtcactact ttcggttatg gtgttcaatg   1200
ttttgcgaga taccagatc atatgaaaca acatgacttt ttcaagtctg ccatgccaga   1260
aggttatggt caagaaagaa ctatTTTTTTT caaagatgac ggtaactaca agaccagagc   1320
tgaagtcaag tttgaagggtg ataccttagt taatagaatc gaattaaaag gtattgattt   1380
taaagaagat ggtaacattt taggtcacaa attggaatac aactataact ctcacaatgt   1440
ttacatcatg gctgacaaac aaaagaatgg tatcaaagtt aacttcaaaa ttagacacaa   1500
cattgaagat ggttctgttc aattagctga ccattatcaa caaaatactc caattggtga   1560
tggtccagtc ttgttaccag acaaccatta cttatccact caatctgcct tatccaaaga   1620
tccaaacgaa aagagagacc acatgggtctt gttagaattt gttactgctg ctggtattac   1680
ccatggtatg gatgaattgt acaaataaac tagt                                1714

```

<210> 5
 <211> 1696
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic nucleotide derived from E. coli and S. cerevisiae

```

<400> 5
gtcgacggct gtatgtttat gattgctcga atcacgtttt tcttgttttt tcgtcaagaa    60
ttccagtcaa gttttccacc accttgaccc ttaaagcatc gacttttggt ctcttgaatg   120
tgtttctaag aatacttgta aaggacaccc tctaatttcg tgtgcacttt tcacatatta   180
tcaagacaat cgttcctgta ctcatgca ctgttactgt aaagactact atacaacaag   240
cgaaaaatga tgttcgaaaa cttttatttc tattttgaaa ggcatgtgtc tcgaggtcct   300
tgctttattg tgggtggtca tgccattctg taaaccttac ggtactgctc cgtctatatc   360

```

```

tttgagggttg ttatttcccc acaaatatgc gtttctaacc gaatattcat tcagtcggac 420
cggacaatag ctcttaactg cgtttaccgg agtaaataatc gtaagaattt gcatgcggtg 480
aaatacaggg aaaataagaa attacaccct aatacaaaaa gaaaactaag tttcacaata 540
cgtaaggata ttttagtggg gagaatattt cggagaataa agtttccaac tccgcggtgt 600
gaacaaccgc tcagcacgca gcgttattct cgagaaaagt ggccctgaaa taaggaaata 660
aagttactaa tgttttttcg ctgtacgata tcaaattgtga cgaagtaggc accccacgct 720
ataaattggc tactaaagtt tatgtcagta cttgggatcg ttgaaatact cggataaatt 780
atgttcctta tttttcatgg ttttcgtcat accacagttt accccagaat gagaaaggat 840
ctccttttga aataaaaagt acttaagggc aatgatattg agttgctaga cgtttggtta 900
gacgcctgtt ttgaaataaa aaagctgtct caaattaatc gagcaagcac agatcaaaca 960
agatacaaac aaagcttttc aacgtaatat ttactatcgg atccaaaagt atggctagct 1020
ccgaggacgt tataaaagag ttcattgagat ttaaagtaag aatggagggc agtggttaacg 1080
gtcacgaatt tgaaatagaa ggggaaggcg agggtagacc atatgaaggc actcaaacag 1140
ccaaactgaa gggtactaag ggagggtccat tgccttttgc atgggatatt ttgtcccctc 1200
aatttcaata cgggagtaaa gtgtatgtga aacaccccg c tgacatccct gattataaga 1260
aactctcttt tccagaagga ttcaagtggg aaagagtcac gaacttcgaa gacggaggtg 1320
tagtaacggt aaccaggat tcttctcttc aagatggtag ctttatctat aagggttaaat 1380
tcattggagt caattttcca tcagacggtc ccgttatgca gaagaaaact atgggatggg 1440
aagcctcgac agagaggttg tatccgcgtg atgggggtgt gaaaggcgaa attcataagg 1500
ctttaaagtt aaaagacggt ggtcattatt tagttgaatt caaatctatt tacatggcga 1560
aaaagcctgt ccaattacca gggtactact acgtggattc aaaactagat attacctcac 1620
ataatgagga ttataacaat gtcgaacaat acgaacgagc agaaggcagg catcatcttt 1680
ttctataggc ggccgc 1696

```

<210> 6

<211> 1706

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic nucleotide derived from E. coli and S. cerevisiae

<400> 6

```

gtcgactttc actcaaccac ctccaaaaaa taacagggtc atctaaagta aaagacttta 60
acttgctctt agtttccaaa ttaaataatct gcacgatagt accatttgct ctaacggaaa 120
taaccatctg agatggatgc atgatagcag aatcaccgcc catattcttc cttgtcactt 180
cattgccttt ggccaaatcc acgattgcaa cagagtttgt accgtccttt gtttctctaa 240

```

```

cagtgcgaa gtggctactc tcgaaagtag ttgatctgaa gtcaaggaat tgaggggaaa 300
ttcctaagga catcagatcg accaattcgg taaattcaat gggtaggtca ctcatcggtt 360
agaactttcg tgataattta tttttatagt tgaatatctt ctttctctct caactctgat 420
ccggattgtc gaggtttcaa taagttactc tgaacaacta atcaaaatat ctctttattt 480
ctgtagattc cttcagttcc actttttact tttcttaatt ctctttgtat ttattcctag 540
cgacgaaaaa tgcgagatct cgaccaaaaa aagggggtag ggtaataaaa ttaaccctat 600
tattttttta ctttaaaacc tataatgtgc taatatttta ttataaacct cttttttttg 660
cgttcaaacc ctgacacatt ttaagcccta tatttacggg attagttgat taaactccga 720
agcgaaagga attcgggtcat tagcggctaa tagccgttgg ggtaaatcac ctacaagcaa 780
gtacacaaga gaacgttggc gttgttaagt caaagcacta atacattggg gctttaagag 840
tgttttataa ggtctaacct gtaaaaatta tttaaacaac ttgaacaggc cttaaagttt 900
tcctcattcc gctcatcatc actaatattg ctctccgttt ttgaatacac acttgacact 960
aataagtatc acagaaaaaa agaaaatata ataaattagt attgcatggg atccaaaagt 1020
atggctagct ccgaggacgt tataaaagag ttcattgagat ttaaagtaag aatggagggc 1080
agtgttaacg gtcacgaatt tgaaatagaa ggggaaggcg agggtagacc atatgaaggc 1140
actcaaacag ccaaactgaa ggttactaag ggaggtccat tgccttttgc atgggatatt 1200
ttgtcccctc aatttcaata cgggagtaaa gtgtatgtga aacacccgc tgacatccct 1260
gattataaga aactctcttt tccagaagga ttcaagtggg aaagagtcatt gaacttcgaa 1320
gacggagggtg tagtaacggg aaccaggat tcttctcttc aagatggtag ctttatctat 1380
aagggttaaat tcattggagt caattttcca tcagacgggc ccgttatgca gaagaaaact 1440
atgggatggg aagcctcgac agagagggtg tatccgcgtg atgggggtgtt gaaaggcgaa 1500
attcataagg ctttaaagtt aaaagacggg ggtcattatt tagttgaatt caaatctatt 1560
tacatggcga aaaagcctgt ccaattacca ggttactact acgtggattc aaaactagat 1620
attacctcac ataatgagga ttatacaatc gtcgaacaat acgaacgagc agaaggcagg 1680
catcatcttt ttctataggc ggccgc 1706

```

<210> 7
 <211> 19
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic PCR primer sequence

<400> 7
 gcgtgccata gtttcttcc

19

<210> 8
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic PCR primer sequence

<400> 8
tcgtccctga gacttactc 19

<210> 9
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic PCR primer sequence

<400> 9
agtaccgtgg catcatggac 20

<210> 10
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic PCR primer sequence

<400> 10
gcagaaattg caccttgtgg 20

<210> 11
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic PCR primer sequence

<400> 11
tttaagtccg ccatacgagc 20

<210> 12
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic PCR primer sequence

<400> 12
ctgcctacat cgccaatcac 20

<210> 13
<211> 20

<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic PCR primer sequence

<400> 13
aatggctact ctgctgttcg 20

<210> 14
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic PCR primer sequence

<400> 14
ctgcctacat cgccaatcac 20

<210> 15
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic PCR primer sequence

<400> 15
tgtcccatcg ggtagtttc 20

<210> 16
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic PCR primer sequence

<400> 16
tgggcagcct tgagtaaadc 20

<210> 17
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic PCR primer sequence

<400> 17
aagcaggaag ggtatgaacg 20

<210> 18
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic PCR primer sequence

<400> 18
cagcagcaat gatagcaagc 20

<210> 19
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic PCR primer sequence

<400> 19
cagcagcaat gatagcaagc 20

<210> 20
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic PCR primer sequence

<400> 20
cgggtcaattt cgcagcactg 20

<210> 21
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic PCR primer sequence

<400> 21
aagctgctct ggttaccgtg 20

<210> 22
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic PCR primer sequence

<400> 22
atacccatgt cctccgcaag 20

<210> 23
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic PCR primer sequence

<400> 23
aagttgtggc ctcaaggaag 20

<210> 24
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic PCR primer sequence

<400> 24
tgttgcgatt gccattcctc 20

<210> 25
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic PCR primer sequence

<400> 25
acttggcaat ccagtgatcc 20

<210> 26
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic PCR primer sequence

<400> 26
tcggaggcat gttgcatttc 20

<210> 27
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic PCR primer sequence

<400> 27
ttgccttctt tccgaacagt 20

<210> 28
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic PCR primer sequence

<400> 28
gcccaagtcg attgaaggta 20

<210> 29
 <211> 20
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Synthetic PCR primer sequence
 <400> 29
 ttccagcctt ctacgtttcc 20

<210> 30
 <211> 20
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Synthetic PCR primer sequence
 <400> 30
 acgtgagtaa caccatcacc 20

<210> 31
 <211> 29
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Synthetic PCR primer sequence
 <400> 31
 ttaagtcgac agagtttact tgcactacc 29

<210> 32
 <211> 27
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Synthetic PCR primer sequence
 <400> 32
 ttaagtcgac ggagataata ccctctg 27

<210> 33
 <211> 30
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Synthetic PCR primer sequence
 <400> 33
 aattggatcc tacgtattgt ttctgtagag 30

<210> 34
 <211> 30

<212> DNA
<213> Artificial Sequence
<220>
<223> Synthetic PCR primer sequence
<400> 34
aattgtcgac tttcttcctt ttctactatc 30

<210> 35
<211> 27
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthetic PCR primer sequence
<400> 35
ttaagtcgac aaccatcctt agcttcc 27

<210> 36
<211> 32
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthetic PCR primer sequence
<400> 36
ttatggatcc tattaaggt gataaataat cc 32

<210> 37
<211> 28
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthetic PCR primer sequence
<400> 37
aattgtcgac tttcactcaa ccacctcc 28

<210> 38
<211> 29
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthetic PCR primer sequence
<400> 38
tatagtcgac tagattcctt cagttccac 29

<210> 39
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic PCR primer sequence
<400> 39
ttaaagatcc atcgcaatac taatttatta tat 33

<210> 40
<211> 29
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthetic PCR primer sequence
<400> 40
ttaaagtcgac acttgggttc tgtttctgg 29

<210> 41
<211> 29
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthetic PCR primer sequence
<400> 41
attagtcgac atacggagcg taaacaacc 29

<210> 42
<211> 30
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthetic PCR primer sequence
<400> 42
atatggatcc gatattgggt aagatacgaa 30

<210> 43
<211> 30
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthetic PCR primer sequence
<400> 43
ttaaagtcgac ggctgtatgt ttatgattgc 30

<210> 44
<211> 29
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthetic PCR primer sequence

<400> 44
ttaagtcgac gctcttaact gcgtttacc 29

<210> 45
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic PCR primer sequence

<400> 45
ttaaggatcc gatagtaaatt attacgttga 30

<210> 46
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic PCR primer sequence

<400> 46
tattgtcgac gcctcttctt tcatttttagc 30

<210> 47
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic PCR primer sequence

<400> 47
attagtcgac attagatgct ttcgagatgc 30

<210> 48
<211> 32
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic PCR primer sequence

<400> 48
taatggatcc tgatcttgta tatactatgt ag 32